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Abstract
Mammary gland involution proceeds through massive, highly controlled epithelial 
cell apoptosis and tissue remodelling. Thus, mammary gland represents an ideal 
physiological environment in which to study apoptosis. Recently, the Smad gene 
family has been identified as mediators of TGF-P superfamily signaling and has been 
implicated in mediating epithelial cell apoptosis. The Smad family of signal 
transduction proteins focuses around a central mediator, Smad4, and this report 
presents a number of analyses which have been undertaken to investigate the potential 
apoptotic role of Smad4 in the mammary gland.
To investigate the role of Smad4 I have utilised an over-expressing Smad4 transgenic 
mouse. This transgenic mouse has been designed to increase Smad4 protein in the 
secretory epithelial cells of the mammary gland during pregnancy and lactation by 
using the biological properties of the BLG promoter. Histological investigation of 
Smad4 slides indicated accelerated involution and significant increase of apoptosis at 
day 2 and 3 of involution. Molecular analysis through Western blots for STAT3 and 
STAT5a levels showed a deregulation of both proteins at the same time points. The 
mechanism with which transgenic mice regulated apoptosis was prove by Western 
blots to be via the p27Kipl molecular pathway and independent of p21wc^  or Bax. 
Microarray analysis for day 3 involuting mice showed an over expression of Vitamin 
D Receptor. A result which was confirmed by both semi quantitative RT-PCR and 
Western blot analysis. Raw microarray data showed a down regulation of Methyl 
Binding Domain 2 (MBD2) in Smad4 transgenic mice indicating that MBD2 could 
play a role in mammary gland involution. However, analysis of conditional mammary 
knockout MBD2 mice at day 3 involution did not show any involvement of MBD2 in 
the regulation mammary gland.
Another way of investigating Smad4 was by passing the Smad4 construct to Stat3 
mammary knockout animals with the hypothesis that Smad4 could restore STAT3’s 
delayed involution. Based on the deregulation of STAT3 protein levels in the smad4 
transgenics the above hypothesis was investigated at day 3 of involution. Phenotypic 
investigation showed that over expression of smad4 is not able to restore the delayed
phenotype of STAT3 knockouts. My final investigation was to identify molecules 
whose expression is altered by a conditional deletion of STAT3 in the mammary 
gland. This investigation was approached through microarrays which demonstrated an 
over expression of the Bone Morphogenic Protein receptor, a result which 
demonstrates once more the synergistic cooperation of Smads and STATS.
v
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Chapter 1-TGF-P and Smads.
1.1 Introduction
1.1.1 The Transforming Growth Factor-P (TGF-p) Superfamily.
The Transforming growth factor p (TGF-P) family consists of more than 35 members 
of structurally related polypeptide growth factors which include the Bone 
Morphogenic Proteins (BMPs), Activins, Inhibins, the Nodals, anti-Mullerian 
hormone, and many other related factors in vertebrates, insects and nematodes 
(Massague 1998). Each of these factors is capable of regulating a fascinating array of 
cellular responses including cell-cycle control, regulation of early development, 
differentiation, extracellular matrix formation, hematopoesis, angiogenesis, 
chemotaxis, and immune functions (Bottner 2000, Dunker and Krieglstein 2000, 
Lawrence 1996, Mummery 2001, Saltis 1996). Collectively, these factors account for 
a substantial portion of the intracellular signals governing cell fate.
One basic concept concerning the role of the TGF-P family as hormonally active 
agents warrants mention at the outset. Unlike classical hormones, whose actions are 
few and clearly defined, the members of the TGF-P family have many different effects 
depending on the type and state of the cell. For example, in the same healing wound 
TGF-P may stimulate or inhibit cell proliferation depending on whether the target is a 
fibroblast or a keratinocyte (Ashcroft 1999); in mammary epithelial cells TGF-p will 
cause growth arrest or metastatic behaviour depending on the level of oncogenic Ras 
activity present in the cell (Oft 1996). Finally, human BMP4 and its Drosophila 
ortholog, dpp (decapentaplegic gene), can signal dorsalization in the fly (Padgett 
1993) yet bone formation in a vertebrate (Sampath 1993). TGF-p family members are 
multifunctional hormones, the nature of their effects depending on what has been 
called “the cellular context”.
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1.1.2 Biological Actions of TGF-p.
TGF-P and related factors occupy a central position in the signaling networks that 
control cell fate, by regulating proliferation, differentiation and apoptosis and are 
therefore important for both development and maintenance of nearly all tissues 
(Hogan 1996). TGF-p has a multitude of actions, most important of which is the 
regulation of genes whose products contribute to the growth and stability of the 
extracellular matrix (ECM). TGF-p regulates these processes by stimulating the 
production of collagen, fibronectin and other ECM components and by decreasing the 
production of proteases that degrade the ECM. This cytokine was originally 
discovered as an autocrine growth factor of tumor cells that allowed these cells to 
grow in soft agar, reflecting a transformed phenotype. It is produced by a variety of 
cell types but CD4 T-cells are a particularly significant source. The actions of TGF-p 
are very pleiotropic, in that this cytokine inhibits the growth of many cell types (e.g. 
epithelial, endothelial, neuronal, haematopoietic, and lymphoid origins) and stimulates 
the growth of others (e.g. mesenchymal cells). The growth inhibitory effect of TGF-P 
is thought to be the molecular basis for many more of its global effects including the 
regulation of immune responses, development and cellular differentiation. In addition 
to its effects on cell proliferation and differentiation, TGF-p also regulates many 
biological processes through its ability to transcriptionally regulate a number of 
cellular genes (Massague 1990).
As stated above, TGF-P is able to stimulate cell proliferation of some cells and inhibit 
the growth of others. Although, this ability to affect different cell types in opposite 
ways is puzzling, it is now clear that the initial cellular responses to TGF-P are similar 
and there are no fundamental differences in the types of receptors that get activated or 
downstream regulatory proteins that transduce signals in the nucleus. Instead, the 
different types of cellular responses occur because TGF-P initiates a number of 
changes in all responsive cells and depending on the individual responses of specific 
cell types and on the environment of the cells, the balance of the effects of these 
changes could result either in cellular proliferation or inhibition of proliferation.
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TGF-p is a cytokine commonly implicated with differentiation of cells. For example 
in mammals it is found at highest concentrations in the tip of the intestinal villus 
where it is associated with the most differentiated cells (Murphy 1998). This 
observation has given rise to the postulate that it is involved in an “autocrine axis” 
that regulates the orderly progression of differentiated cells not only in the intestine 
but also in the skin, perhaps explaining its vital role in wound healing (Wahl 1989). 
Other members of the family, especially the BMPs, are also very important in the 
healing processes that occur in bone and cartilage (Bostrom and Asnis 1998).
Despite the fact that one might predict numerous and complex transduction pathways 
regulating this diversity of responses, surprisingly, a disarmingly simple system has 
recently been elucidated involving a family of membrane receptor protein kinases and 
a family of receptor substrates, the Smad proteins.
1.2 TGF-P Signal Transduction Pathway and Components.
1.2.1 Smad Dependent and Independent Pathways.
The transforming growth factor-P pathway occupies a central position in the signaling 
networks that control growth, differentiation and final fate of metazoan cells. Over the 
past few years, remarkable progress has been made in identifying the central 
components of this pathway, defining their interactions, and deciphering how a cell 
interprets its signals. The TGF-p pathway involves a family of transmembrane 
receptor protein kinases and a family of receptor substrates, the Smad proteins, which 
translocate into the nucleus where they act as transcription factors. The ligand, TGF-P, 
assembles a receptor complex that activates Smads, and in turn, the Smads assemble 
multisubunit complexes that regulate transcription (reviewed in Derynck 2003, Shi 
2003) (Figure 1.1). Two general steps thus suffice to carry the hormonal stimulus to 
target genes.
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How can such a simple system mediate a variety of cell specific responses? An 
incoming Smad complex is met in the nucleus by a set of partner proteins that are 
specific to a particular cell type in each particular set of conditions. These partners 
determine the DNA sequences that the Smad complex will bind, the transcriptional 
co-activators or co-repressors it will recruit, the other transcription factors it will 
cooperate with, and how long this process will last. The mixture of Smad partners and 
regulators present in a given cell at the time of TGF-p stimulation thus determines the 
outcome of the response and at the same time defines, in molecular terms, the cellular 
context. Identifying these partners and regulators is, therefore, critical for 
understanding TGF-P action.
1.2.2 TGF-p Signaling Receptors.
TGF-P and related factors signal through a family of transmembrane protein 
serine/threonine kinases known as the TGF-p receptor family. Protein kinases play an 
important role in signal transduction by phosphorylating specific amino acids in 
downstream components. Catalytic domains can predict what kind of residues will be 
phosphorylated by a given kinase. Many receptors for hormones and growth factors 
are membrane bound tyrosine kinases with reasonably well-understood signal 
transduction pathways. In contrast, until relatively recently, serine/threonine kinase 
activity had been detected only in cytoplasmic proteins downstream of receptor 
signaling.
This family of receptors came to light with the cloning of an Activin receptor 
(Mathews 1991), now referred to as Activin Type II Receptor (ActR-H), with 
properties similar to those of TGF-p receptors identified in cross-linking studies 
(Cheifetz 1987) and genetically implicated in TGF-p signal transduction (Laiho 
1990). The cloning of ActR-H also revealed a striking similarity between this 
molecule and Daf-1, a previously identified orphan receptor from Caenorhabditis 
elegans (Georgi 1990). Exception to the above scenario is the glial cell-derived
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neurotrophic factor (GDNF), which signals through the tyrosine kinase Ret receptor 
(Massague 1998). GDNF is the most divergent family member and shows very little 
sequence similarity to other members. These findings provided the basis and impulse 
for the rapid identification of many other members of this receptor family.
1.2.3 TGF-P Receptor Types and Structure
Based on their structural and functional properties, TGF-p receptor family is divided 
into two subfamilies: type I and type II receptors. Both of the receptors are 
glycoproteins of approximately 55kDa and 70kDa, respectively, containing an 
extracellular, transmembrane and kinase domain. A unique feature of the type I 
receptor is a highly conserved 30-amino acid region preceding the kinase domain 
region. This domain is called the GS domain because of the characteristic 
SGSGSGSG sequence it contains (Wrana 1994). This region has been proved to be a 
key regulatory region able to control the catalytic activity of type I receptor kinase. 
The function of this domain in TGF-P signaling will be explained in detail below.
The extracellular domains of both type I and II receptors consists of approximately 
150 amino acids which can be N-glycosylated and contain 10 or more cysteine 
residues that may determine the general fold of this region (Wells 1997). Three of this 
cysteines form a characteristic cluster near the transmembrane sequence (Wrana 1994) 
while the spacing of the remaining varies and seems more conserved in type I 
receptors. No main differences exist in the transmembrane and cytoplasmic 
juxtamembrane regions. However, Ser213 in this region of type II receptor is 
phosphorylated by the receptor kinase in a ligand independent manner and is required 
for signaling activity (Luo 1997). Seri 65 in the juxtamembrane region of type I 
receptor is phosphorylated by the type II receptor in a ligand dependent manner, and 
this appears to selectively modulate the intensity of different TGF-P responses.
The kinase domain in both type I and II receptors is a typical serine/threonine receptor 
kinase (Mathews 1991, Franzen 1993). Type I receptors have been shown to
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phosphorylate their substrates, the Smads, on serine residues, while the type II 
receptors are able to phosphorylate themselves and type I receptors on serine and 
threonine residues.
As previously mentioned the GS domain is a unique feature of the type I receptor. 
Ligand induced phosphorylation of the serines and threonines in this region of type I 
receptors by the type II is required for activation of signaling (Souchelnytskyi 1996, 
Wrana 1994, Wieser 1995). Following this specific SGSGSG sequence, all type I 
receptors have a LEU-Pro motif that serves as binding site for the immunophilin 
FKBP12 (Chen Y 1997). FKBP12 may act as a negative regulator of the receptor 
signaling function. Furthermore, at the boundary of the GS and the kinase domain, 
there is either a threonine or glutamine residue. Mutation of this residue to aspartate or 
glutamate in type I receptors has been shown to endow the receptor with elevated 
kinase activity in vitro and constitutive signaling activity in the cell (Wiersdorff 
1996). Thus, the GS domain is a key regulator region that may control the catalytic 
activity of the type I receptor kinase or its interaction with substrates.
1.2.4 Receptor Activation.
TGF-p and related family members activate signaling by binding and bringing 
together pairs of type I and type II receptors. Primarily, ligand binding occurs to the 
type II receptor (TpR-II) (Massague 1998), which exists in the cell membrane in an 
oligomeric form (Lu 1996) with activated kinase (Henis 1994, Chen 1994). In turn the 
type I receptor, which may also occur in an oligomeric form (Lu 1996) and cannot 
bind TGF-P in the absence of type-II receptor, is recruited into the complex. 
Activation of the type I receptor from the type II occurs in the GS domain through 
transphosphorylation at threonine and serine domains (Franzen 1995). The assembly 
of the receptor complex is triggered by ligand binding, but the complex is also 
stabilised by direct interaction between the cytoplasmic parts of the receptors (Feng 
1996). This model predicts that the type II and type I receptors act in sequence, which 
is supported by the finding that a constitutively active type I receptor (Thr 204
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replaced by an aspartate residue) is able to exert TGF-p signals in the absence of type 
II (Wieser 1995). This model of binding was discovered using TGF-p resistant cell 
mutants: TGF-p 1 can bind to type II receptors in cell mutants lacking a type I receptor 
but cannot bind to a type I receptor in mutants lacking type II (Laiho 1990, Massague 
1998).
1.3 Smad Proteins.
1.3.1 Classification of Smads.
The Smad protein family are the only known substrates of type I receptor kinases and 
play a central role in the transduction of receptor signals to target genes in the nucleus. 
These proteins were first identified as the products of the Drosophila Mad (Sekelsky
1995) and C.elegans Sma genes (Derynck 1996), which he downstream of the BMP- 
analogous ligand-receptor systems (Patterson and Padgett 2000, Whitman 1998). The 
human genome encodes eight Smad family members (Smad 1-8) [Mad-homologues 
(MAD-H], and related proteins are known in the rat, mouse, Xenopus, Zebrafish, 
Drosophila and C.elegans. Smads are ubiquitously expressed in all adult tissues 
(Fladers 2001, Luukko 2001), and many of them (Smad2, 4, 5, 6 and 8) are produced 
from alternatively spliced mRNAs.
Functionally, Smads fall into three subfamilies (Figure 1.2). a) receptor-regulated 
Smads (R-Smads: Smadl, Smad2, Smad3, Smad5 and Smad8), which become 
phosphorylated by the type I receptors, b) common mediator Smads (Co-Smad: 
Smad4), which oligomerise with activated R-Smads and directs them to the nucleus, 
and c) the inhibitory Smads (I-Smads: Smad6 and Smad7), which are induced by 
TGF-/3 family members and provide a negative feedback loop to TGF-/3 signaling.
Amongst the receptor-regulated Smads, Smadl and its close homologues Smad5 and 
Smad8 get activated upon BMP ligand binding in their corresponding receptors. On
8
the other hand, Smad2 and Smad3 are substrates of TGF-/3 and Activin signal 
transduction.
Signaling by receptor-regulated Smads requires the participation of a collaborating 
Smad. The only known member of this group in vertebrates is Smad4. Smad4 
associates with receptor-regulated Smads after their activation from their 
corresponding receptors. Although Smad4 is similar to the R-Smads in overall 
structure (see below), it fails to become phosphorylated in response to agonists. 
Smad4 is required for Smad2 and/or Smad3 dependent growth inhibitory responses in 
mammalian cells, and a dominant-negative Smad4 construct interferes with Smadl 
and Smad2 signaling in frog embryos and mammalian cells (Zhang 1996, Lagna 
1996). Smad4, therefore, participates in TGF-P, Activin and BMP signaling pathways 
as a shared partner of receptor-regulated Smads.
I-Smads exert a negative feedback effect by competing with R-Smads for receptor 
interaction and by marking the receptors for degradation. More specifically, Smad6 
preferentially inhibits BMP signaling (Imamura 1997, Hata 1998) and Smad7 inhibits 
TGF-P and BMP signaling. Smad7 inhibits phosphorylation of R-Smads by occupying 
the type I receptors for BMPs, Activins, and TGF-p. Smad6 preferentially inhibits 
BMP signaling by competing with Smad4 for binding to receptor activated Smadl and 
forms an inactive Smadl-Smad6 complex. Smad6 and Smad7 levels are increased in 
response to Activin, BMP or TGF-p signaling, suggesting that these Smads function 
as negative feedback controls for different pathways.
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1.3.2 Structural Features of Smads.
Smads have two conserved domains, the N-terminal Mad homology 1 (MH1) and C- 
terminal Mad homology 2 (MH2) domains. There is also an intervening linker region, 
which is of variable length and sequence composition. The MH1 domain has 
approximately 130 amino acids and is highly conserved among R-Smads and the Co- 
Smad; however, the N-terminal parts of I-Smads have only weak sequence similarity 
to MH1 domains. The MH1 domain regulates nuclear import and transcription by 
binding to DNA and interacting with nuclear proteins (will be discussed later). In the 
basal state, the MH1 domain has been shown to inhibit MH2's transcriptional (Liu F
1996) and biological (Baker 1996) activities and this inhibitory effect has been 
attributed to an interaction between these two domains (Hata 1997).
However, the MH1 domain does not have a purely inhibitory function. As mentioned 
above one of the basic functions of this domain is its DNA binding ability. It has been 
shown that Smad4's MH1 domain contributes to the DNA-binding activity of a 
Smad2-Smad4 transcriptional complex (Liu 1997). The same appears to be true for all 
Smad4-R-Smads complexes. The contribution of the MH1 domains to the DNA- 
binding affinity and specificity of Smad transcriptional complexes may vary 
depending on the particular target gene.
The MH2 domain is about 200 amino acids long and is highly conserved among all 
Smads. This domain contains receptor phosphorylation sites (in R-Smads) (Macias- 
Silva 1996), which regulate Smad oligomerisation, has effector function (Liu F 1996, 
Baker 1996), and is involved in several important protein-protein interactions 
(discussed later) with various cytoplasmic adaptors and transcription factors. More 
specifically, interactions between the MH2 domains support Smads homo-oligomeric 
complexes, which exist in all subfamilies at the basal state (Lagna 1996, Hata 1997, 
Hata 1998, Wu 1997). Furthermore, MH2 is the domain which mediates the 
association of R-Smads with type I receptors (Macias-Silva 1996) and Smad4 upon 
activation (Hata 1997) and with DNA binding factors. It has been shown that Smadl 
and Smad2 require the presence of the MH2 domain in order to activate transcription
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(Liu F 1996, Liu F 1997). In the case of inhibitory Smads, the MH2 domain is 
sufficient for their inhibitory effect (Hata 1998, Topper 1997).
The crystal structure of Smad4 MH2 domain has provided insights into the basis for 
some of the above interactions. Its structure contains several a-helices and loops, 
which surround a /3-sandwich (Shi 2001), and it resembles the forkhead associated 
(FHA) domain, a phosphopeptide-binding domain common in transcription and 
signaling factors (Li 2000). Compared with other Smad proteins, Smad4 has a 
characteristic insertion in the MH2 domain and lacks the SSXS motif, the site of 
phosphorylation by the type I receptors. Due to this sequence alteration, Smad4 is not 
a substrate of the type I receptors (Zhang 1996). Furthermore, Smad4’s essential role 
in Smad-mediating transcriptional activation is partly due to a unique Smad activation 
domain (SAD), a 48 amino acid proline-rich regulatory element in its linker region 
(Itoh 2000).
The linker region is highly variable in size and sequence. Despite this variability all 
linker regions contain multiple phosphorylation sites, which allow specific crosstalk 
with other signaling pathways. Additionally, this region contributes to the formation 
of Smad homo-oligomers (Hata 1997, Wu 1997).
1.4 The Core Smad Pathway.
1.4.1 Smad Recognition, Access and Activation by the Activated Receptor 
Complex.
Phosphorylated type I receptor exhibit a significantly enhanced binding affinity for the 
R-Smads. This binding selectivity has been attributed to a positively charged surface 
patch on the R-Smads’s MH2 domain which is absent in Smad4 (Wu 2000). It has 
been demonstrated that mutation of His331, on the basic patch of Smad2, leads to a 
reduction of its affinity for, and phosphorylation by, type I receptor (Huse 2001).
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The first step in the intracellular TGF-p/Smad pathway is the recruitment of R-Smads 
to the TGF-P receptor complex (Figure 1.1). Several proteins with anchoring, 
scaffolding, and/or chaperone activity have now been identified in regulating and 
facilitating this process. Smad anchor for receptor activation (SARA) has been shown 
to regulate the subcellular distribution of Smad2 and Smad3 (Tsukazaki 1998). SARA 
is associated to the inner leaflet of the plasma membrane via its FYVE phospholipids 
binding domain, (Tsukazaki 1998). In addition, SARA can simultaneously interact 
with (non activated) R-Smads and the TGF-p receptor complex through its Smad 
binding domain (SBD) and its C-terminal region, respectively. After type I receptor 
activation, two serine residues in the C-terminal sequence of Smad2 and Smad3 are 
phosphorylated by the type I receptor kinase, followed by the dissociation from SARA 
and type I receptor. Activated Smad2/3 forms subsequently a heteromeric complex 
with Smad4. Overall, TGF-P receptor activation is required for R-Smad presentation 
by SARA to the receptor (Tsukazaki 1998).
It has also been demonstrated that the TRAP-1 protein (TGF-p receptor- associated 
protein-1) can specifically interact with Smad4 and aid the recruitment of the co-Smad 
to the TGF-P and Activin receptor complex (Wurthner 2001). In the basal state 
TRAP-1 associates with the inactive TGF-P receptor complex, and, upon receptor 
activation dissociates from the complex and associates with Smad4. The TRAP- 
1/Smad4 interaction is not continues but is disrupted by activated R-Smads. It has 
been suggested that TRAP-1 may function as a chaperone to reduce the auto- 
inhibitory interactions between the MH1 and MH2 domains of Smad4 and facilitate in 
this way the interaction of Smad4 with activated R-Smads (Wurthner 2001).
Several other factors with the same properties have been demonstrated to play various 
possible roles in Smad anchoring. Microtubules can anchor inactive Smads in the 
cytoplasm (Dong 2000). More specifically, ligand induction results in dissociation of 
Smads from the microtubule network. Sasaki (2001) demonstrated that filamin, an 
actin cross linking factor with scaffolding abilities, regulates transduction of Smad 
signals. Other examples of Smad associating scaffolding protein are the ARIPs
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(Activin receptor interacting proteins), which associate with Smad2 and enhance 
Smad2-mediated signaling in response to Activin (Tsuchida 2001).
The available data support the notion that interactions between Smads and proteins 
with scaffolding/adaptor proteins are an important regulatory mechanism. Proper 
receptor localisation in plasma membrane, their proximity to cytoplasmic anchors that 
hold the Smads and the ability of such compartments are exciting new aspects of the 
regulation of Smad signaling. Such mechanisms could provide cell-context specificity, 
allowing differential regulation of the basic Smad pathway.
1.4.2 Nuclear import and export of Smads.
R and Co-Smads primarily exist in the cytoplasm, where upon ligand stimulation they 
subsequently translocate to the nucleus (Heldin 1997, Massague and Wotton 2000). 
This is accomplished through a nuclear localisation-like sequence (NLS-like; Lys- 
Lys-Leu-Lys), which exists in the MH1 domain of both R-and Co-Smads (Xiao 
2000a, Kurisaki 2001). This motif has been reported to be important for Smad3 
translocation to the nucleus after TGF-p stimulation. Smad3 directly binds to 
importin-p via this region but not to importin-a (Xiao 2000a, Kurisaki 2001), and Ran 
GTPase promotes nuclear translocation of activated Smad3 to the nucleus (Kurisaki 
2001). Smad2 has a unique insert of exon3 in the same domain, which prevents its 
association with importin-p (Kurisaki 2001). Nuclear import of non-phosphorylated 
Smad2 is blocked by SARA, which masks the intrinsic nuclear import activity of 
Smad2, which was reported to have an NLS in its MH2 domain (Xu 2000).
In contrast with Smad2 and Smad3, Smad4 has a leucine-rich nuclear export signal 
(NES) in its linker region (Pierreux 2000). The nuclear export of Smad4 is mediated 
by the general export factor CRM1; inhibition of CRM1 by treatment with leptomycin 
B results in rapid accumulation of Smad4 (but not Smad2 or 3) in the nucleus 
(Pierreux 2000). Smad4, which in the basal state is located in the cytoplasm, is 
proposed to rapidly and constitutively shuttle between the nucleus and the cytoplasm. 
It has also been proposed that upon heteromeric complex formation between R-and
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Co-Smads, the nuclear accumulation of the complex may be stimulated by the 
shielding of the NES and/or unmasking NLS on R-and/or Co-Smad (Pierreux 2000).
Smadl (but not Smad2 and 3) has also been found to contain a functional NES in its 
MH2 domain (Xiao 2001). Thus, Smadl may also constantly shuttle between nucleus 
and cytoplasm, with receptor-induced Smadl phosphorylation shifting the balance 
towards nuclear accumulation of Smadl.
1.4.3 Smads in the Nucleus.
Once formed, the heteromeric R-Smad/Smad4 complex translocates to the nucleus 
where it regulates transcription of target genes by directly binding to consensus DNA 
sequences, interacting with other DNA binding proteins, and by recruiting several 
transcriptional co-activators or co-repressors. The nature of the biological readout in a 
given cell is highly dependent on the particular R-Smad that is activated, and on the 
cell-specific expression of Smad interactors. These interactions affect Smad 
availability, Smad activity, the selection of target genes and so help determine which 
particular constellation of genes is up- or down-regulated.
1.4.4 Direct Binding of Smads in the DNA.
The key function of Smad proteins in TGF-p family signal transduction is 
transcriptional regulation. Biochemical evidence indicates that the Smads can bind 
DNA. Thus, the R-Smads (except for Smad2) and Smad4, recognise a specific DNA 
sequence (AGAC) or its complementary (GTCT), termed Smad binding elements 
(SBEs) (Dennler 1998, Zawel 1998). This binding is facilitated via an interaction 
between Smad's MH1 domains and the SBE within target gene promoter. Smad3 and 
Smad4 bind directly within the major DNA groove but with low affinity, through a 
conserved beta-hairpin loop in the MH1 domain. Although Smad2 is structurally
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similar to Smad3, and both Smad2 and Smad3 are activated by TGF-p or Activin type 
I receptors, Smad2 does not bind to DNA. In contrast to Smad3, Smad2 has a short 
region composed of 30 amino acids in the MH1 domain encoded by its unique exon-3, 
which prevents its DNA binding (Yagi 1999). Additional MH1 sequences, such as a- 
helix 2, contribute to SBE DNA-binding by Smad3 (Kusanagi 2001). I-Smads cannot 
bind to DNA.
1.4.5 Interaction with DNA Binding Proteins.
Smads bind directly to DNA sequences with relatively low affinity (Kd= 1.14 x 10*7 
mol/L), suggesting that the Smads need to interact with other cellular factors to form 
transcriptional complexes and regulate transcription of target genes (Shi 1998).
The first and most extensively characterised Smad transcriptional partners are 
members of the FAST (Forkhead Activin Signal Transducer) family. FAST-1 is a 
member of the winged-helix family of DNA-binding proteins. Xenopus, mouse and 
human FASTs have been demonstrated to be required for TGF-P or Activin dependant 
activation of the Xenopus mix2 gene. The homeobox gene mix2 is a response gene 
responsible for early Xenopus development (Chen 1997). The mammalian homologue 
(alternative named FAST-2) can mediate the activation of the homeobox gene 
goosecoid following gastrulation (Labbe 1998, Zhou 1998). FAST can bind 
constitutively to specific elements in the promoters of these genes, but cannot activate 
transcription on their own. However, upon activation of Activin or TGF-p signaling 
pathways, a complex containing FAST, R-Smads and Smad4 assembles on the DNA 
and transcription is strongly activated (Labbe 1998, Zhou 1998). More specifically, 
FAST interacts with Smad2-Smad4 or Smad3-Smad4 complexes, but not with BMP- 
activated Smad complexes.
Consistent with the idea that Smad binding alone is not sufficient for gene activation, 
there are now a growing number of examples in which Smads are found to cooperate 
with DNA binding partners to regulate transcription.
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Furthermore, at TGF-p responsive AP-1 binding sites, Smad3 interacts through its 
MH1 domain with c-jun and through its MH2 domain with c-Fos, and thus forms a 
multiprotein complex (Yamamura 2000). The cooperativity between Smad3-Smad4 
and c-Jun/c-Fos then results in TGF-p-induced transcription for these promoter 
sequences. In a conceptually similar way, Smad3-Smad4 cooperates with the basic 
helix-loop-helix protein TFE3 to induce transcription from the PAI-1 promoter in 
response to TGF-p although no physical interaction between TFE3 and Smad3-Smad4 
has been demonstrated (Hua 1998).
In addition, the responsiveness of the promoters for the p i 5 and p21 CDK cell cycle 
inhibitors to TGF-p has been localised to Spl-binding sites, suggesting that Spl is 
required for their transcriptional activation by Smads in response to TGF-p. It has also 
been demonstrated that Smads can associate with ATF2, PEBP2/CBF, vitamin D 
receptor, Gli3 and Hoxc8 (Denryck 1998). Smad4 was found to interact and 
functionally cooperate with p-catenin and LEF1/TCF, which are components of the 
Wnt signaling pathway, in inducing Xenopus twin (Xtwn) gene expression (Nishita
2000). Smad3 has also been reported to functionally interact with LEF1/TCF in a 
TGF-P-dependant manner independent of p-catenin (Labbe 2000).
1.4.6 Interaction with Transcriptional co-Activators and co-repressors.
Transcriptional activity of Smads also depends on interactions with co-activators 
within the complex. It has been shown that R-Smads bind directly to p300/CBP. 
Smad3 interacts with p300 with high affinity. Smadl and Smad2 can also interact 
with p300 (Nishihara 1998, Feng 1998). Interaction of p300 with Smad3 leads to the 
enhancement of transcriptional activation by Smad3 of target genes, including p3TP- 
Lux. In turn, p300 binds to various transcription factors, including STAT, and 
positively regulates the transcription of target genes in combination with Smads. 
Although Smads and STATS do not directly interact with each other they are bridged
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by p300 in the nucleus resulting in efficient activation of translation (Nakashima 
1999).
Smad signaling can also lead to repression of gene expression. Smad3 has been 
reported to associate with histone deacetylase (HDAC) activities through its MH1 
domain, but whether Smads interact directly with HDACs remains unclear (Liberati
2001). Alternatively, Smads interact with various transcriptional co-repressors that 
recruit HDACs. These co-repressors include the homeodomain DNA-binding protein 
TGIF (Transcription Growth Factor Interacting Factor) (Wotton 1999). TGIF interacts 
with activated Smad2/3 and may limit the magnitude of TGF-P responses in cells. 
Furthermore, R-Smad/Smad4 complexes interact with the proto-oncogene products c- 
Ski and Sno-N, which are important transcriptional co-repressors. Smad2/3 as well as 
Smad4 interacts with c-ski through multiple regions. Neither BMP-activated R-Smads 
nor I-Smads bind to c-ski. Smad3 interacts with c-ski through its MH2 domain and 
since p300 also interacts with the same domain of Smad3, there is a competition 
between c-ski and p300 for Smad3 binding. Smad3 interacts with c-ski, which in turn 
recruits HD AC (Akiyoshi, 1999). Thus, histone acetylation is induced by Smad3 and 
p300, and abolished by the addition of c-ski.
Additional inhibitors of the nuclear functions of Smads include SIP1 (Smad 
Interacting Protein-1) and Evi-1. SIP1 interacts with the MH2 domain of R-Smads but 
not with Smad4, in both yeast and mammalian cells (Verschueren 1999).
Such co-repressors appear to modulate the nuclear activity of Smads, and their levels 
of expression define the level of Smad transcriptional activity.
1.4.7 Ending Smad Signaling.
Termination of Smad signaling has been attributed so far to two mechanisms. Smad 
signaling termination can be achieved by dephosphorylation caused by as yet 
unidentified phosphatases (Randall 2002), and ubiquitination and proteasome-
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mediated degradation of activated R-Smads. In unstimulated cells, the Smad-ubiquitin 
E3 ligase (Smurfl) targets Smadl and Smad5 for destruction (Zhu 1999). This action 
is considered important for the possible maintenance of the basal state in unstimulated 
cells. Activated Smad2 is ubiquitinated in the nucleus and undergoes proteasome- 
mediated degradation in a process which includes Smurf2, which has extensive 
sequence similarity to Smurfl (Lo 1999, Lin 2000, Zhang 2001). Ubiquitination of 
activated Smad3 appears to be mediated by a different E3, the SCF/Rocl complex 
(Fukuchi 2001).
Smurfl and 2 also mediate ubiquitination of activated TGF-/? receptors, leading to 
their degradation in the proteasome (Ebisawa 2001, Tajima 2003). I-Smad 7 facilitates 
this process by moving from the nucleus to the plasma membrane upon TGF- /3 or 
BMP stimulation (Itoh 1998) where it forms a complex with both Smurfl and 2. This 
complex binds directly to the activated type I TGF-/? receptor and inhibits 
phosphorylation of R-Smads (Kavsak 2000, Suzuki 2002). In the membrane complex, 
Smurfl subsequently directly mediates the ubiquitination and turnover of the 
receptors (Ebisawa 2001, Tajima 2003). Smad7 itself also undergoes ubiquitination 
and degradation in this process. However, this negative feedback loop is countered by 
the ability of TGF-/? (and BMPs) to transcriptionally activate Smad7, thus ensuring a 
steady supply of the protein as it undergoes degradation.
In the nucleus, Smad7 associates with p300, which acetylates lysine residues 64 and 
70 in Smad7,protecting it against Smurf-mediated ubiquitination of the same residues 
(Gronroos 2002). Smad7 acetylation is lost as the protein leaves the nucleus in 
response to TGF-/? stimulation and separates from p300. Although the R- and co- 
Smads also associate with p300 and the related acetyl transferase CBP in the context 
of assembling transcriptional complexes, no evidence has been found that they can 
undergo acetylation.
These observations underscore the complex mechanisms controlling TGF- /? signaling 
and suggest the involvement of additional factors that may regulate the stability of 
Smad proteins at both the basal and the activated states.
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1.5 Mammary Gland Structure and Function.
The mammary gland is characterised by a unique dependence of hormonal signals for 
terminal differentiation, which is attained only after pregnancy. At the time of birth, 
the glands consist of a few rundimentary ducts in the vicinity of the nipple. 
Pronounced ductal outgrowth and branching commences at puberty, and during 
pregnancy an expanded lobulo-alveolar compartment develops. Functional 
differentiation of the secretory epithelium coincides with parturition and large 
amounts of milk are produced and secreted during lactation. The fully functional 
gland is 90% epithelial. After weaning of the young, the entire alveolar epithelial 
compartment is remodelled to resemble a virgin like state, a process termed 
involution. With each pregnancy, a new round of lobulo-alveolar development occurs.
During involution a coordinated process of alveolar programmed cell death (PCD) and 
lobulo-alveolar remodelling restructures the mammary gland. Simple removal of the 
suckling stimulus triggers this process. Mammary gland involution proceeds through 
two distinct phases. In the first stage, alveolar cells undergo programmed cell death, 
but there is no remodelling of the lobulo-alveolar structure. During the second stage, 
the lobulo-alveolar structure of the gland is obliterated as proteinases degrade the 
basement membrane and extracellular matrix. The two stages exhibit characteristic 
changes in gene expression or activity. First stage changes include up-regulated 
expression of sulphated glycoprotein, tissue inhibitor of metalloproteinases, 
interleukin-lb converting enzyme, cell cycle control proteins (c-jun, c-Fos, JunB, 
JunD, and c-Myc) and decreased expression levels of milk protein genes. Second 
stage changes include increased expression levels of matrix metalloproteinases 
(MMPs), gelatinase A, stromelysin-1 and serine protease urokinase-type plasminogen 
activator.
Programmed cell death of individual alveolar cells during the first days of involution 
is correlated with increased expression levels of the death inducers box and bcl-x.
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Furthermore, changes in activity of two STAT family members accompany mammary 
gland involution; decreased activity of the prolactin signaling molecules STAT5a and 
STAT5b and activation of STAT3.
This repetitive cycling of the gland from full lactation to involution and back again is 
a phenomenon that occurs in few other tissues and thus elects the mammary gland as 
an ideal model to study highly controlled in vivo cellular apoptosis (Figure 1.3). 
Systemic hormones and the influence of the stroma on mammary epithelial cells have 
been characterised for some time (Sakakura 1991). However, only now through the 
availability of knockout mice have we been able to dissect individual steps in the 
pathways of the translation of hormonal signals into morphogenetic and 
developmental events. Two unique aspects of mammary gland development have 
greatly aided in exploiting these knockout animals and elucidate the specific roles of 
the epithelium and the stroma. First, the mammary gland develops predominantly in 
postpartum animals. Therefore, an entire developmental program, mimicking 
embryonic development of other organs, can be viewed and followed in postpartum 
animals. This characteristic has several ramifications; the tissue can be easily 
manipulated, and reasonable amounts of tissue are available for analysis. Second, 
genetic manipulations whose consequences in other tissues would result in lethality 
can now been studied due to the fact that mammary cells transplanted into the cleared 
fat pad continue to grow and divide very effectively. Thus, normal virgin ductal or 
lobulo-alveolar cells will readily grow and fill the fat pad with mammary ducts in 
virgin animals (or differentiate into alveolar cells if the recipient animal becomes 
pregnant).
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Figure 1.3. Mammary Gland Development (H&E staining).
The development of the gland in mice as a model system proceeds in 
distinct phases; in newborn mice a rudimentary system of small ducts is 
present which grows slowly until the onset of puberty when 
pronounced ductal growth occurs. Development of the ducts continues 
in cycling virgins leading to the formation of a ductal tree which fills 
the entire mammary fat pad. Extensive ductal branching and alveolar 
growth occurs during pregnancy and is largely completed at 
parturition. Terminal differentiation of the alveolar epithelium is 
completed at the end of gestation with the onset of milk secretion at 
parturition. After weaning the entire alveolar epithelium undergoes 
apoptosis and the gland is then remodeled. Within a few weeks the 
gland has the appearance of that of a mature virgin. Magnification x40. 
Scale bar 100pm
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1.5.1 TGF-P and the Mammary Gland.
Programmed cell death (PCD) (apoptosis) occurs during normal growth and 
development of the mammary gland and is perhaps one of the most dramatic examples 
of apoptosis driven remodelling (Strange 1995). It has been demonstrated that all three 
TGF-p isoforms are expressed during all stages of mammary gland development 
except lactation (Robinson 1991). Mouse studies indicate key roles for TGF-ps in 
establishing proper mammary gland structure, regulating stem cell kinetics, 
maintaining the mammary epithelium in functionally undifferentiated state, and 
inducing apoptosis in the involuting gland (Daniel 1996, Joseph 1999, Nguyen 2000).
Transgenic mouse models have demonstrated that over expression of polypeptides 
such as transforming growth factor alpha (TGF-a) and insulin like growth factor I 
(IGF-I) can block this remodelling, suggesting that these growth factors may be acting 
as survival factors for the mammary epithelium (Jhappan 1990, Weber 1998). In 
contrast, transgenic mice that over express the growth inhibitor TGF-p show increased 
apoptosis in the mammary epithelium throughout mammary development, suggesting 
a mechanism working to counterbalance the survival factors (Pierce 1993, Jhappan 
1993). Furthermore, Gorska (1998) showed that over expression of a dominant 
negative receptor type II for TGF-P in mammary epithelial cells disrupts normal TGF- 
P signaling and leads to mammary hyperplasia.
Many members of the TGF-P super family seem to be involved in mammopoiesis. 
Inhibins and Activins which are members of the TGF-p family are important 
regulators. A specific function for the Activin and inhibin(P)B subunit was identified 
for the mammary gland as mice deficient for the inhibin (p)B gene exhibit retardation 
of ductal elogation and alveolar morphogenesis during puberty and pregnancy 
respectively. Further, mammary transplantation experiments demonstrated a localised 
defect in the gland that was associated with the stroma. This resulted in ductal 
elongation and alveolar proliferation, with differentiation severely curtailed in 
inhibin(P)B-deficient stroma (Robinson and Henninghausen 1997). These
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experiments also showed abnormal morphology of terminal bud ends (TEBs) 
implying a disturbance in the balance of cell proliferation and cell death in this 
structure as one cause of the observed developmental defect.
1.6 The Cre-Lox Recombination System.
Recent advances in mouse embryology and molecular genetics have achieved the 
specific mutation of defined genes in the germline of mice creating a plethora of 
models for biological research. Protocols using transgenesis (Gordon 1980) and 
homologous recombination in embryonic stem (ES) cells (Capecchi 1989, Capecchi 
1989a) permit over expression, inactivation and modification of genes at will. Our 
understanding of some of the important issues regarding the mechanisms controlling 
cell division, differentiation and death has dramatically advanced in recent years 
through exploitation of these techniques to generate transgenic mice. Mutations, 
identical to those observed in inherited or somatically acquired diseases such as in 
cancer, can now be mimicked in mouse model systems. These technologies are 
valuable in assessing the role of genes in complex processes such as tumorigenesis, 
embryonic development and functioning of the immune system. In particular, the 
generation of mice with targeted mutations in genes encoding proteins of interest has 
proved to be a useful way of elucidating the function of these gene products in vivo.
These technologies are invaluable in assessing the role of genes in biological 
processes as those mentioned above. However, there are a number of limitations as 
well e.g. nullizygosity appears to be lethal in many instances or causes complex 
pleiotropic effects and therefore do not permit the development of an in vivo model 
system in which gene inactivation is restricted to a defined subset of cells (Copp 
1995). To overcome these limitations, strategies for conditional, cell type-specific 
gene targeting (Gu 1994) and inducible gene disruptions (Kuhn 1995) have been 
developed. These systems utilize site-specific recombinases such as the Cre/Loxp 
recombination system of bacteriophage PI.
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Cre is the 38kDa product of the cre gene of bacteriophage PI (Sternberg, 1978) and is 
a site-specific DNA recombinase. Cre recombinase has the ability to recognise and 
mediate site-specific recombination between 34bp sequences referred as loxP (locus 
of crossover (x) in PI) (Sternberg, 1981). The loxP sequence consists of two 13 bp 
inverted repeats interrupted by an 8  bp nonpalindromic sequence which dictates the 
orientation of the overall sequence (Figure 1.4) (Hoess, 1984). When two loxP sites 
are placed in the same orientation on a linear DNA molecule, a Cre-mediated 
intramolecular recombination event results in the excision of the loxP flanked, or 
“floxed”, sequence as a circular molecule with one loxP site left on each reaction 
product (Figure 1.4). The reverse reaction, an intermolecular recombination event, 
will result in the integration of the circular DNA molecule into the linear molecule, 
each possessing a loxP site. Unlike many other recombinases no accessory factors or 
DNA topological requirements are needed for efficient Cre-mediated DNA 
recombination and this makes this system uniquely suited to genomic manipulation of 
eukaryotic cells (Sauer, 1988).
In general, the experimental outline of Cre-Lox mediated gene targeting consists of 
the targeted incorporation of loxP sites into the genome of ES cells via a 
corresponding targeting vector. After identification of homologous recombinants the 
final genetic modification is obtained by a Cre-mediated gene recombination event, 
either stably in cultured ES cells and the germline of mice derived from these ES cells 
or in a conditional manner in mice by the expression of Cre as transgene.
A particularly powerful feature of a conditional gene inactivation strategy using Cre is 
that the same loxP-tagged mouse can be used for gene ablation independently in a 
large number of different tissues, or at different developmental times, by simply 
mating it with a corresponding Cre transgenic that displays the desired tissue or 
temporal specificity of expression. Thus, the same genetically modified animal can be 
used to answer a variety of different questions relating to the expression and function 
of the target gene. Crucial to the success of this strategy is the prior careful evaluation 
of the pattern of expression of the Cre transgenic animal. Mosaic expression or 
exogenous tissue expression can defeat the purpose of the experiment and so careful 
choice of promoter must be considered. In our case the promoter of choice is the ovine
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beta lactoglobulin (BLG) (Whitelaw 1992, Farini 1995, Clark 1992) which has shown 
that promotes over expression of target genes in the mammary gland from mid 
pregnancy to lactation.
An attractive alternative is the use of a viral-mediated gene transfer of Cre 
recombinase (Anton and Graham, 1995). This uses a basic strategy where sections of 
the wild type virus genome, such as sequences encoding the El and E3 genes are 
replaced with a Cre expression construct. Such recombinant viruses are replication 
deficient but still capable of host cell infection. With this approach, cultured cells can 
be exposed directly to the virus and very high efficiencies of infections can be 
achieved.
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Excision Integration
57 ATAACTTCGTATAATGTATGCTATACGAAGTTAT 37 
37 T ATT G AAGC AT ATT AC AT ACGAT AT GCTT C AAT A 57
Floxed gene of interest Tissue Specific Cre
Gene of interest deleted from specific tissue
Figure 1.4.Conditional Gene Targeting
Cre recognises a 34 base pair site on the PI genome called loxP (locus of X-over of 
PI) and efficiently catalyses reciprocal conservative DNA recombination between pairs 
of loxP sites. The loxP site consists of two 13 base pair inverted repeats flanking an 8 
base pair non palindromic core region that gives the loxP site an overall directionality 
that, by convention, is depicted as an arrow. Cre mediated recombination between two 
directly repeated loxP sites results in excision of the DNA between them as a 
covalently closed circle. Correctly targeted ES cells are injected into mice and animals 
containing the modified gene (which are at this point phenotypically wild type), are 
then crossed with mice expressing Cre in the desired target tissue and Cre-mediated 
excision results in a tissue-specific gene ablation.
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1.7 Smad Transgenic and Knockout mice.
Most of the Smad proteins have been investigated through transgenic or knockout 
mice and results demonstrated the dependency of R-Smads to Smad4 for appropriate 
TGF-/3 signaling as well as their role in many biological processes such as 
development, cell cycle arrest and apoptosis of various cell types in various tissues. 
By using a conditional over expressing Smad2 in mouse epidermis, Ito (2001), 
demonstrated that induction of Smad2 increased endogenous Smad4 and TGF-/31 
expression while heterozygous loss of Smad2 reduced their expression levels. Further, 
these transgenic mice exhibited a number of abnormal phenotypes in hair growth, ear 
development, skin and tails which were attributed to increased proliferation of the 
basal epidermal cells and abnormal keratinocyte differentiation. Generation of 
homozygous Smad2 mutant mice by gene targeting proved to be lethal at day E7.5- 
E10.5 (Weinstein 1998, Heyer 1999). Lethality was attributed to impaired anterior- 
posterior axis formation and gastrulation defects. Heterozygotes for Smad2 were 
fertile with no apparent abnormalities up until 1 Vi years of age.
Targeted disruption of Smad3 generated viable and fertile mice. However, between 4 
and 6  months of age, Smad3 mutant mice developed colorectal adenocarcinomas with 
subsequent metastasis to the lumph nodes (Zhu 1998). Multiple cancers including 
(pancreatic, colorectal, lung, breast, prostate, ovarian, head and neck, esophagal, 
gastric bladder, hepatocellular and renal cell) have been shown to occur in mice with 
somatic mutations for Smad4 while homozygous Smad4 mutant mice die before day 
E7.5 due to failure to gastrulate and abnormal visceral endoderm development (Sirard 
1998).
Finally, over expression of Inhibitory Smads leads to a number of abnormalities. 
Smad6  over expression in chondrocytes showed postnatal dwarfism and inhibition of 
proper phosphorylation in Smad 1, 5 and 8  (Horiki 2004). Further, over expression of 
Smad7 in mice epidermis caused a number of abnormalities in multiple epithelial 
tissues and caused death 10 days after birth (He 2002).
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1.8 Aims.
The broad aim of this project is to further understand the role of Smad4 during 
mammary gland involution. Stat3 will be also utilised in analyzing the interplay with 
Smads as well as analyzed on its own. Finally, because the Methyl Binding Domain 
(MBD2) protein was implicated as a modulated target in preliminary studies I also 
analysed its potential role in controlling mammary gland development and involution. 
In order to achieve this goal I undertook the following approaches.
The first approach was to characterise a mammary gland-specific Smad4 transgenic 
mouse. This mouse contains a stable transgene consisting of the BLG promoter which 
drives expression of a human Smad4 cDNA. This transgene should therefore over 
express Smad4 in the mammary gland, and should be useful in addressing any 
possible role Smad4 plays in the lactation to involution progression and to what extent 
it is involved in the control of apoptosis in the gland. This analysis is based on the 
hypothesis that “over expression of Smad4 will promote the anti-proliferative 
effects of TGF-/? by accelerating apoptosis in the involuting mammary gland”.
As part of the same analysis, I performed a transcriptome microarray analysis from 
day 3 involuting mice. This time point was selected based on my phenotypic and 
molecular analysis as shown in Chapter 3. My aim in this analysis was to identify 
molecular targets with altered expression as a consequence of Smad4 over expression 
(Chapter 4). Identification of these molecular targets should then lead to a clearer 
picture of the interplay between the TGF-(3 and other signaling pathways during 
involution and Programmed Cell Death.
Western blot analysis of Stat3 in the Smad4 transgenic mice identified an interaction 
of the two proteins. Based on this data I also expanded the mammary gland analysis 
by over expressing Smad4 in a Stat3 null environment. Conditional deletion of Stat3 
from the mammary gland is achieved through use of the Cre-Lox recombination 
system. This model allowed an assessment of the potential interaction between Smad4 
and Stat3 in involution of the mammary gland (Chapter 5). In the same chapter I also
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analyzed Stat3 heterozygous mice by performing microarray experiments. This 
approach will be in a scaling manner for identifying differences in gene expression 
from Stat3 wild type and Stat3 heterozygous mice. For the purpose of these 
experiments I performed primary mammary cell cultures in order to avoid mammary 
epithelial cell contamination by adipocytes.
MBD2 was identified as a candidate target of Smad4 in preliminary studies. As a 
small project I also analyzed MBD2 knockout mice during involution in order to 
investigate any potential role played by this protein in normal involution (Chapter 4).
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Chapter 2 -Materials and Methods.
2.1 Mice.
2.1.1 Maintenance of Mice Colonies.
Mice were a mixed colony of C57 B6/S129 (50%-50%) and maintained under non­
barrier conditions.
2.1.2 Generation of Smad4 Transgenics.
The Smad4 transgenics were generated in Edinburgh by Eleonor Duff in the following 
way. cDNA coding for the human Smad4 gene was expressed under the control of a 
BLG promoter (Figure 2.1 A). Two FI founder mice were detected by PCR analysis 
for the presence of the BLG promoter (Figure 2. IB). One founder mouse was further 
tested for the number of integration sites and transgene copy number by Southern 
blotting (Figure 2.1C). Mice expressing BLG-Smad4 and wild types reached 
adulthood with no apparent abnormalities.
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Figure 2.1. The generation of Smad4 transgenic mice. A: a schematic of the 
BLG-FLAG-Smad4 transgene. A 4.2kb BLG promoter fragment was fused 
to a FLAG-Smad4 expression construct. Restriction sites were used to 
linearize or excise the insert and prepare genomic DNA for Southern blot 
analysis. B: PCR analysis for the presence of the BLG promoter C: 
Southern blot analysis of transgenic genomic DNA. Transgenic mice were 
identified by Southern blot analysis using the 1682bp BLG promoter 
sequence as a probe (arrows).
2.2 G enotyping of Mice.
2.2.1 DNA Extraction from mouse tails.
DNA was extracted from tails using the PUREGENE DNA extraction kit. Tails were 
lysed overnight in 500 pi of cell lysis solution (Puregene) and 10 pi of proteinase K 
(20 mg/ml, Sigma), shaken at 37C°. Tails were left to cool at room temperature, 200 
pi of protein precipitation solution (Puregene) was added to each tube. These were 
vortexed and centrifuged at top speed for 5 minutes in a microfuge.
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The supernatant was removed into a clean tube containing 500 pi of isopropanol, 
vortexed and centrifuged at top speed for 5 minutes. The supernatant was discarded 
and the DNA pellet was left to dry overnight. DNA was resuspended in 500pl DNA 
hydration solution (Puregene). Finally, the samples were stored at 4 °C prior to PCR.
2.2.2 Genotyping of Mice via PCR.
Genotyping of mice took place by genomic PCR (Polymerase Chain Reaction) from 
DNA extracted from mouse tails. All PCR reactions performed in 50 pi volumes 
using 2 pi of the tail DNA preparation. All PCR reactions were carried out using MJ 
Research PCR machines (PTC-100). 15 pi of PCR products were analysed on 3% 
TBE agarose gel stained with ethidium bromide (10 mg/ml) (Sigma) and viewed 
under UV light.
2.2.3 BLG-SMAD4 PCR.
The BLG-Smad4 PCR was designed in our lab. The protocol for a 50 pi reaction mix 
contained 5 pi PCR buffer (Sigma), 1 pi of each primer (10 pmoles per pi) 
(OSWELL), 1 pi of each dNTP (40 mM), 3 pi of MgC12 (Sigma), 2 pi of Taq 
polymerase (Sigma), 33 pi of autoclaved DDW (deionised distilled water), and 2 pi of 
DNA template. Reaction conditions were as follows: 94 C° 2:30 minutes, then 30 
cycles of 94 C° 30 seconds (denaturation), 64 C° 30 seconds (annealing) and 72 C° 1 
minute (extension) and 5 minutes of 72 C°.
The BLG-Smad4 transgene generated a 350bp band.
Primer 1: 5' TCGTGCTTCTGAGCTCTGCAG 3'
Primer2: 5' GCTTCTGGGGTCTACCAGGAAC 3'
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2.2.4 BLG Cre Genotyping.
The protocol for a 50 pi BLG Cre PCR reaction mix was as follows: 5 pi PCR buffer 
(Sigma), 0.1 pi of each primer (10 pmoles per pi) (OSWELL), 0.5 pi of each dNTP 
(40 mM), 3 pi of MgC12 (Sigma), 2 pi of Taq polymerase (Sigma), 37.3 pi of 
autoclaved DDW) deionised distilled water), and 2 pi of DNA template. Reaction 
conditions were as follows: 94C° 2 minutes, then 34 cycles 94C° 1 minute 
(denaturation), 55 C° 1 minute (annealing) and 72 C° 2 minutes (extension) and 10 
minutes of 72 C°.
Wild type fragment generated no bands whilst the Cre fragment a 1Kb band.
Primer 1: 5'TGACCGTACACCAAAATTTG 3’
Primer 2: 5 ATTGCCCCTGTTTCACTATC 3’
2.2.5 Stat3 FIox PCR.
The protocol for a Stat3 Floxed 50 pi reaction mix contained 5 pi PCR buffer 
(Sigma), 1 pi of each primer (lOpmoles per pi) (OSWELL), lpl of each dNTP 
(40mM), 5pi of MgC12 (Sigma), 2pl of Taq polymerase (Sigma), 33pi of DDW, and 
2pl of DNA template. Reaction conditions were as follows: 95 C° 2:30 minutes, then 
34 cycles of 95 C° 30 seconds (denaturation), 67 C° 1 minute (annealing) and 72 C° 1 
minute (extension) and 10 minutes of 72 C°.
The Stat3 Floxed PCR does not recognise null alleles. Floxed allele gives a 350bp 
band whilst wild type allele a 250bp band.
Primerl: 5' C AC AC AAGCC ATC AAACTCTGGTCTCC 3'
Primer2 : 5' CCTGAAGACCAAGTATCCTGTGTGAC 3'
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2.2.6 Stat3 Null PCR.
The protocol for a Stat3 Null 50 pi reaction mix contained 25 pi PCR buffer 
(EPICENTRE), 0.5 pi of each primer (10 pmoles per pi) (OSWELL), 0.5 pi of Taq 
polymerase (EPICENTRE), 21.5 pi of autoclaved DDW) deionised distilled water), 
and 2 pi of DNA template. Reaction conditions were as follows: 95 C° 3 minutes, then 
37 cycles of 95 C° 30 seconds (denaturation), 72 C° 1 minute (annealing) and 72 C° 1 
minute (extension) and 10 minutes of 72 C°.
The Stat3 Null PCR gives a 1Kb band.
Primer 1: 5'ATCGCCTTCTATCGCCTTCTTGACGAG 3'
Primer 2: 5 'AGCAGCTGACAACGCTGGCTGAGAAGCT 3'
2.2.7 MBD2 PCR
The protocol for the MBD2 wild type and null PCR reactions is as follows: 50 pi 
reaction mix contained 25 pi PCR buffer (EPICENTRE), 0.5 pi of each primer (10 
pmoles per pi) (OSWELL), 0.5 pi of Taq polymerase (EPICENTRE), 21.5 pi of 
autoclaved DDW) deionised distilled water), and 2 pi of DNA template. Reaction 
conditions were as follows: 95 C° 3 minutes, then 35 cycles of 94 C° 30 seconds 
(denaturation), 56 C° 30 seconds (annealing) and 72 C° 1 minute (extension) and 10 
minutes of 72 C°.
The MBD2 Wild type PCR gives a 428 bp product while null PCR gives a 292 bp 
product.
Primer 1 (wild type): 5'ACGCTGGCCTAGTGCCGTGC 3'
Primer 2 (wild type): 5’AAGAACAAGCAGAGAACTCCG 5’
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Primer 1 (null): 5’ TTGTGGTTGTGCTCAGTTC 3’ 
Primer 2 (null): 5’ TCCGCAAACTCCTATTTCTG 3’
2.3 Harvesting Mammary Glands.
Mice were culled by cervical dislocation and mammaries were taken by an incision 
made in the midline through the skin but not the body wall. Skin was peeled back on 
either side and pinned to reveal the mammary glands. The glands were removed and 
either fixed in formalin for paraffin embedding and histological analysis or snap- 
frozen in liquid nitrogen in an Eppendorf microfuge tube for protein analysis.
2.4 Mammary Gland Analysis.
2.4.1 Histological Analysis.
Formalin fixed mammary glands transferred to 70% ethanol before embedded in 
paraffin wax. 3pm thick sections cut and placed onto histobond-coated slides. Slides 
stained with haematoxylin and eosin (H&E) for histological analysis.
2.4.2 Wholemount Analysis.
Mammary glands were dissected and placed onto glass slides. They were fixed in 2% 
Paraformaldehyde for a minimum of 2 hours. After fixation glands washed with PBS 
and dH20 for 5 minutes respectively. Slides stained with carmine aluminium 
overnight (lgr carmine, 2.5 gr Aluminium Potassium sulphate in 500mls of dH20).
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Stained slides washed with dH20 and dehydrated with 15 minute washes in 70%, 95% 
and 2x 100% alcohol respectively. After dehydration, slides were cleaned with Benzyl 
Benzate-Benzyl Alcohol (2:1) and covered with cover slips in DPX.
2.4.3 Peroxidase Staining of paraffin Embedded Tissues (Tunnel Analysis).
For measuring apoptotic cells I used a Peroxidase In Situ Apoptosis Detection Kit 
(Intergen) as follows.
• Tissue sections were deparaffinized by washes in:
3x Xylene (5 min each)
2x 100% Ethanol (5 min each)
lx 95% Ethanol (3 min)
lx 70% Ethanol (3 min)
lx PBS (5 min)
• Following deparraffinazation tissue sections were pretreated as follows:
-Apply 60 fil Proteinase K (20 ug/ml). Leave for 15 minutes at room temperature. 
-Wash 2x dH20 (2 min each)
• Endogenous Peroxidase was quenched as follows:
- Apply 60 fi\ Hydrogen Peroxide (3% in PBS) for 5 minutes at room temperature.
- Wash 2x PBS (5 min)
• Gently tap off Excess liquid and add 75 /d of Intergen’s Equilibration Buffer 
directly on the specimen for 15 seconds.
• Gently tap off Excess liquid and add 55 fi\ of Working Strength TdT enzyme 
for 1 hour at room temperature.
• Stop the reaction by adding the specimens into coplin jars containing 
STOP/Wash Buffer (1:34 dilution in dH20). Agitate specimens for 15 seconds 
and incubate for 1 0  minutes at room temperature.
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• Wash Specimens in 3 changes of PBS for 1 minute each wash. Tap off excess 
liquid and add 65 /zl of Anti-Digoxigenin Peroxidase conjugate directly to the 
specimens. Incubate for 30 minutes in a humidified chamber at room 
temperature.
• Following incubation wash specimens in 4 changes of PBS (2 minutes each 
wash), in a coplin jar at room temperature.
• Develop colour by adding 75 /zl Peroxidase substrate for 4 minutes at room 
temperature.
• Wash specimens in 3 changes of dH20 (1 minute each wash) in a coplin jar.
• Counterstain with 60 /zl of 0.5% Methyl Green for 4 minutes at room 
temperature.
• Wash specimens in 3 changes of dH20 by dipping the slides 10 times each in 
the first and second washes, followed by 30 seconds without agitation in the 
third wash.
• Wash specimens in 3 changes of 100% N-BUTANOL in a coplin jar, dipping 
the slides 10 times each in the first and second washes, followed by 30 
seconds without agitation in the third wash.
• Dehydrate specimens by moving the slides through three coplin jars of 
XYLENE (2 minutes each wash).
• Mount specimens under a coverslip in DPX (Distyrene Plasticizer Xylene) and 
view under a microscope in a lOOx magnification.
2.4.4 P21 Staining.
P21 immunohistochemistry was performed by facilitating the “ABC” kit (Vector 
Laboratories). This procedure employs biotinylated antibody and a preformed Avidin: 
Biotinylated enzyme Complex and has been termed the “ABC” technique. The first 
step of the procedure is to incubate the section with a primary antibody (in this case 
rabbit anti-p21) raised against the antigen of interest. Next, a biotin-labelled secondary 
antibody is added, which in this case is biotinylated anti-rabbit IgG. This introduces 
many biotins into the section at the location of the primary antibody. The avidin:
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biotinylated enzyme complex (ABC) is then added and binds to the biotinylated 
secondary antibody. In the last step of the procedure, the tissue antigen is localized by 
incubation with a substrate for the enzyme.
More specifically:
• Tissues were deparaffinized by washes in:
3x Xylene (5 min each)
2x 100% Ethanol (5 in each) 
lx 95% Ethanol (3 min) 
lx 70% Ethanol (3 min) 
lx PBS (5 min)
• Block peroxidase 15 minutes at room temperature.
Note: Use a 20 L stock containing:
a) 83.2gr Citric acid (Sigma)
b) 215.2gr diSodium hydrogen Phosphate (Sigma)
c) 20gr Na Azide (Sigma)
to whatever volume required to this stock add H202 to a final 1.5% solution.
• Retrieve the antigen by boiling the sections for 20 minutes in Na Citrate 
lOMm, pH 6.0.
• Once boiled transfer slides to a preheated plastic coplin jar containing same 
buffer and cool it down by submerging under cold running water.
• Wash 2-3x PBS
• Block sections for 30 minutes with 5% goat serum in PBS
• Wash 2x PBS
• Incubate slides with Santa Cruz anti-p21 (M19) diluted 1/500 in 5% goat 
serum/PBS for 1 hour at room temperature.
• Wash PBS 3x for 5-10 minutes each.
• Block 10 minutes with 5% goat serum in PBS
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• Incubate slides for 30 minutes with biotinylated secondary antibody from 
rabbit ABC kit (Vector Laboratories)
• Wash PBS 3x for 5-10 minutes each.
• The staining was visualised with an ABC-HRP (horse radish peroxidase) kit 
(Vectalabs) and then DAB (3,3 diaminobenzedene) (DAKO), a chromogen 
which makes a chemical reaction leading to brown colouration in positive 
areas.
2.5 Protein Extraction from Mammary Gland.
• Remove mammary glands from sacrificed animals and snap frozen at -70C° 
until extraction. Crush a frozen piece of tissue using a mortar pellet in liquid 
Nitrogen until it becomes a fine powder.
• Use liquid nitrogen and pour this powder into a universal and leave liquid 
nitrogen to evaporate off.
• Add 400pl of RIP A buffer and shear the tissue with a 21G needle. Centrifuge 
for 15 minutes at full speed at 4C°. Remove supernatant, aliquot, snap frozen 
into liquid nitrogen and store at -70C° until use.
RIPA Buffer
500mM Tris HCL pH 7.5 (Fisher)
150mMNaCl (Fisher)
1% Nonidet p40 (Sigma)
0.5% sodium deoxycholate (Sigma)
0.1% SDS (Fisher)
40
To 10ml of RIP A buffer add 1 mini-cocktail tablet (Roche) of protease inhibitors.
2.5.1 Determination of protein concentration.
• For estimation of protein concentration a microscale variant of Bradford’s dye 
of binding method was used (Bradford 1976). Add 5-10/xl of protein sample to 
lml of Bradford reagent (BioRad), mix and allow to stand for 10 minutes 
before measurement at A5 9 5 . In each case perform absorbance measurements 
against blanks containing an equal volume of the Bradford reagent.
• Correlate absorbance measurements with a freshly generated calibration curve 
(0-25 fig of bovine serum albumin in lml of bovine serum albumin in 1 ml 
Bradford Reagent) to estimate the protein concentration of the unknown 
sample.
2.5.2 Western Analysis.
• For Western analysis, run proteins on denaturing polyacrylamide gels (10% 
gels for > 40 kDa proteins and 15% gels for < 40 kDa proteins).
• Equalise protein samples with RIPA buffer so that all samples are 20 fig and of 
equal volume (20 fil). Boil samples for 5 minutes in 4 x Loading Buffer 
containing /3 -mercaptoethanol, quench on ice, centrifuge briefly and load onto 
the gel. Run gels for 2 hours at 125V in running buffer or until the protein 
markers (Gibco) separate.
• Blot gels on PVDF (Polyvinylidene Difluoride) membrane (Millipore) in 
transfer buffer overnight at 15 mA or for 2 hours at 200 mA. Prior to transfer, 
soak PVDF membrane in methanol (Fisher) for 30 minutes.
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• After transfer, block membranes in TBS/0.1% Tween/10% Marvel (TTM) for 
one hour. All blots were incubated with primary antibodies for one hour at 
room temperature. The Stat3 antibody SC-482 (rabbit polyclonal) (Santa 
Cruz) was used at a concentration of 1 in 500 whilst the Stat5a antibody 
(rabbit polyclonal) SC-1381 (Santa Cruz) was used at a concentration of 1 in 
1000. P21 (Pharmigen 556431) (rabbit polyclonal) used at a concentration of 
1:50. P27 (Neo Marker) (rabbit polyclonal) used at a concentration of 1:500. 
Bax (Santa Cruz) SC-493 (rabbit polyclonal) used at a concentration of 1:500. 
Vitamin D receptor (Santa Cruz) SC-1008 used at a concentration of 1:250. 
Actin (Santa Cruz) H-196 used at a concentration of 1:1000.
• Wash blots 3 times in TTM (10 minutes each) and incubate in secondary 
antibody (Santa Cruz): anti-rabbit-HRP at the following concentrations: for 
Stat3 1:1000, for Stat5a 1:2000, for p21 1: 1000, for p27 1: 1000, for Bax 1: 
1000, for Vitamin D receptor 1:2000, Actin 1:1000.
• Wash blots with TBS (10 minutes each) and visualise using ECL plus 
(Amersham) on ECL film (Amersham). To confirm equal loading after 
blotting, stain blots with Ponso Red (Sigma).
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Reagents
15% Loading Gel 10% loading Gel 10% Stacking Gel
3.33ml DDW
11.69ml 30% acrylamide 
(1:29)
9.37ml 1M Tris HCL pH 8 . 8  
250pl of 10% SDS (Fisher) 
72pl of 25% APS (Fisher) 
13.2pl of Temed (Sigma)
6.65ml DDW
8.35ml 30% acrylamide 
(1:29)
9.37ml 1M Tris HCL pH 8 . 8  
250pl of 10% SDS 
72pl of 25% APS 
13.2pl of Temed
3.57ml DDW
1.70ml 30% acrylamide 
(1:29)
0.62ml 1M Tris HCL pH6 . 8  
50pl of 10% SDS 
33pi of 25% APS 
3.6pl of Temed
4x Loading Buffer
200 mM Tris HC1 pH 6 . 8  
400 mm Dithiothreitol (DTT) 
8 % SDS
0.4% Bromophenol blue 
40% Glycerol
lOx Running Buffer: For 1 L
30.2 g Tris
188 g Glycine (Fisher)
Transfer Buffer For 1L:
800 ml DDW 
2 0 0  ml methanol
2.9 g Tris
14.5 g Glycine
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2.6 Primary Mammary Cell Culture.
• Dissect mammary glands from 16-18 day pregnant mice and place them in a 
sterile 50 ml falcon tube on ice.
• Finely chop mammary glands with sterile scalpels and resuspend in fresh 
collagenase/trypsin digestion mix (980 mg of F10 powered medium-Sigma, 
150 mg of trypsin-Gibco, 300 mg collagenase A-Gibco, and 5 ml of Foetal 
Calf Serum in a final volume of 100 mis with distilled water).
• Filter the collagenase digestion mixture through a 0.2 pm sterile filter before 
use and store at 4 °C until required.
• Place minced glands in autoclaved, sterile 50 ml polypropylene tubes and
digest for 90 minutes on a rotary shaker, 250 rpm at 37 °C. Use 4 mis of
digestion mixture per gram of tissue.
• Remove the digested cell suspension to a 50 ml tube and spin for 30 seconds at 
100 rpm. Remove the supernatant on a new 50 ml tube on ice. Resuspend the 
resulting undigested pellet in the remaining digestion mixture for a further 30 
minutes. After 30 minutes, spin the tube for 30 seconds at 100 rpm and 
transfer the supernatant to the same 50 ml tube on ice.
• Centrifuge the supernatants at 800 rpm for 3 minutes and discard the aqueous 
solution.
• Resuspend the pellet in 5 ml of F I2 medium (containing gentamicin) and
make the volume in the tube to 50 ml with F I2 medium/gentamisin (50
pg/ml).
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• Spin the tubes for 3 minutes at 800 rpm and discard the supernatant.
• Resuspend the pellet in F I2 medium containing gentamisin (50 pg/ml) and 
1 0 % foetal calf serum with the following hormones; hydrocortisone lpg/ml 
(Sigma stock solution: 1 mg/ml in 100% ethanol), insulin 5 pg/ml (Sigma 
stock solution: 5 mg/ml in 5mM HCL), epidermal growth factor 5 ng/ml 
(Promega stock solution: 5 pg/ml in F I2 medium) and fetuin (Sigma 1 
mg/ml).
• Seed cells on tissue culture plastic at a density of 2.4 x 106 cells/ml and let 
grow for 48 hours at 37 °C in a humidified atmosphere of 5% C02.
2.7 Total RNA extraction from mammary gland.
• Dissect mammary gland and immediately transfer to 5 mis of RNA later 
solution (Sigma). Just before homogenisation remove RNA later solution, 
weight sample and add 1 ml of Trizol (Invitrogen) per 100 mgs of sample.
• Homogenise mammary gland in a homogeniser until no large pieces of tissues 
are visible. Between homogenisations, clean homogeniser with a) 4M NAOH,
b) 75% Ethanol (treated with di-ethylPyrocarbonate (DPC)) and c) with 
nuclease free water (DPC treated) for 15 seconds respectively.
• If necessary aliquot the homogenised sample in 1 ml volumes in sterile, 
RNAse free 2 ml centrifuge tubes and keep on ice.
• Spin samples for 10 minutes at maximum speed and transfer the supernatants 
to new 2 ml RNAse free centrifuge tubes.
45
• Add 200 pi of cold chloroform to each sample. Shake samples vigorously for 
10 seconds for mixing and chill in ice for 5-10 minutes.
• Spin samples for 15 minutes at maximum speed. After spinning, transfer the 
top aqueous phase which contains the RNA to a new RNAse free 2 ml tube.
• To precipitate the RNA, add an equal volume of cold isopropanol, mix by 
inversion and leave in ice for 45-60 minutes.
• Following incubation, spin samples for 15 minutes at maximum speed. 
Discard the supernatant and wash the RNA pellet with lml of cold 75% 
ethanol (DPC treated).
• Spin samples for 15 minutes at maximum speed.
• After spinning, discard the supernatant and leave the pellets to air dry for 5-10 
minutes.
• Resuspend RNA in 100 pi of nuclease free water and clean it with a Qiagen 
RNeasy clean up mini kit (see below).
• Evaluate total RNA on a 2% agarose, IX TBE gel for the presence of a 28S 
and 18S rRNA bands. Samples with an almost double intensity of the 28S 
band compared to the intensity of the 18S band are characterised as useful 
samples and can be kept for quantitative analysis.
• Quantitate RNA concentration by UV spectrophotometry at an absorbance of 
260 and 280 nm. RNA samples with a 260/280 ratio of 1.7-2.1 can be 
considered useful and used for RT-PCR and In Vitro Transcription (IVT).
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2.7.1 RNA Extraction from Monolayered Cell Cultures.
• Lyse cells directly on Petri dishes by adding lml of Trizol (Invitrogen) reagent 
per 107 cells and pipette up and down until no clumps are visible. Lyse cells 
further through a 21G (or smaller) needle. Transfer cells to sterile 14 ml 
round-bottom polypropylene tubes and incubate for 5 minutes before splitting 
into 1 ml aliquots in 2  ml sterile round-bottom tubes.
• Add 0.2 ml of chloroform to each tube and mix vigorously by hand for 15 
seconds. Incubate tubes at room temperature for 3 minutes.
• After incubation, centrifuge tubes at 12000g for 15 minutes at 4C°.
• Transfer the upper aqueous phase (~0.6ml) to a fresh tube and add 0.5 ml of 
isopropanol. Leave for 10 minutes at room temperature.
• After incubation, centrifuge samples at 12000g for 15 minutes at 4C°.
• Remove the supernatant and wash tubes with lml of 75% ethanol in DEPC 
treated sterile water. Mix tubes by vortexing and centrifuge for 5 minutes at 
7.500g at 4C°.
• Remove the supernatants and leave the pellets to air dry for 5-10 minutes.
• Resuspend RNA pellets in 50 pi DEPC treated sterile water.
• Analyse RNA quantitatively by spectrophotometry and qualitatively by 
electrophoresis of 2 pg of RNA on a 1% agarose IX TBE gel.
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• Clean RNA samples by using the Qiagen RNeasy clean up kit (see below).
2.7.2 RNA Cleanup using the Qiagen RNeasy Kit.
Note: Use a maximum of 100 pg of RNA for this cleanup protocol. This amount 
corresponds to the binding capacity of the RNeasy mini columns.
• Add 10 pi of /3-mercaptoethanol per lml of RTL buffer.
• Adjust RNA volume to 100 pi with RNase-ffee water. Add 350 pi of RTL 
buffer and mixed thoroughly.
• Add 250 pi of absolute ethanol to the diluted RNA and mix thoroughly.
• Apply the 700 pi sample to an RNeasy mini column placed in a 2 ml 
collection tube. Close tubes gently and centrifuge for 15 seconds at lOOOOrpm. 
Discard the flow-through and collection tube.
• Transfer the RNeasy mini column to a new collection tube and add 500 pi of 
RPE buffer. Close tubes gently and centrifuge for 15 seconds at 10000 rpm. 
Discard the flow- through.
• Add another 500 pi of buffer RPE to the RNeasy mini column. Close tube 
gently and centrifuge for 2 minutes at lOOOOrpm to dry the RNeasy silica-gel 
membrane. Discard the flow-through and collection tube.
• Transfer the RNeasy mini column to a 1.5 ml (RNase free) collection tube. 
Add 50 pi of RNase-ffee water directly onto the RNeasy silica-gel membrane. 
Close tubes gently and centrifuge for 1 minute at full speed.
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Measure new RNA concentrations by UV spectrophotometry as described 
above.
2.7.3 Target Preparation for Affymetrix GeneChip.
OUTLINE OF PROCEDURE
Cells/Tissue
Total RNA Isolation 
1  RNA Clean up (RNeasy kit)
Total RNA
cDNA Synthesis with T7 (dT)24 primer 
Clean Up (Phenol/Chloroform/IAA
Double Stranded cDNA
In Vitro Transcription (IVT)
 ^f T7 RNA Polymerase
Biotin Labelled Ribonucleotides
Biotin Labelled cRNA
RNeasy Clean Up 
 ^r Fragmentation
Fragmented cRNA
Qualitative analysis of cRNA
▼
Target cRNA
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• After incubation add 2 (j.1 of Superscript II Reverse Transcriptase (200 U/pl) in 
each reaction tube.
• Incubate tubes for 1 hour at 42C°.
Second Strand cDNA Synthesis
• Prepare a master mix per reaction tube on ice with the following reagents:
91 pi DEPC treated sterile water 
30 pi (5x) Second Strand Buffer
3 pi (lOmM) dNTPs 
1 pi E.coli DNA Ligase (lOU/pl)
4 pi E.coli DNA Polymerase I (lOU/pl)
1 pi E.coli RNAse H (2U/pl)
130 pi Total
• Mix the master by vortexing. Add 130 pi of master mix to each first strand 
reaction tubes and mix by pipetting.
• Incubate tubes at 16 C° for 2 hours.
• After the incubation period, add 2 pi (10U) of T4 DNA Polymerase to each 
reaction tube and incubate for 5 minutes.
• Finally, add 10 pi of 0.5M EDTA (Sigma) to each reaction tube.
• Place tubes on ice and proceed to “Clean Up of double stranded cDNA” or 
store at -80C°.
Superscript Double Stranded 
cDNA Synthesis Kit 
(Invitrogen)
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Clean Up of Double Stranded cDNA.
Note: This method uses Phase-Lock tubes (Eppendorf) which contain a gel that 
separates the aqueous and organic phases of the phenol extraction allowing better 
recovery of the aqueous phase.
• Spin phase-lock tubes in a microfuge at maximum speed for 30 seconds.
• Add 160 pi of room temperature buffer saturated phenol/chloroform/IAA 
(Ambion) to the cDNA reaction. Vortex tubes briefly.
• Place mixture into the phase-lock tube and spin at full speed for 2 minutes.
• Transfer the upper (aqueous) phase to a new tube and the add the following 
reagents:
0.5 volumes (approximately 80 pi) 7.5M Ammonium acetate (Sigma)
4pl Glycogen (5 mg/ml) (Ambion)
2 . 6  volumes (approximately 600 pi) 1 0 0 % room temperature ethanol
• Mix tubes by tapping and spin at room temperature at maximum speed for 20 
minutes.
• Remove the supernatants from the tubes without dislodging the pellets.
• Add 160 pi of cold 80% ethanol (DPC treated) to the pellets and spin tubes at 
maximum speed for 5 minutes in room temperature.
• After spinning, discard the supernatants and repeat the 80% ethanol washing 
step.
• Discard the supernatants and leave the pellets to air dry for 5-10 minutes.
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• After drying, resuspend pellets in 12 pi of DEPC treated sterile water.
• Place tubes on ice in order to proceed to the in vitro transcription reaction or 
store at -80C°.
Synthesis of cRNA-In vitro transcription.
Note: All reagents used for the in vitro transcription are from the Enzo BioArray High 
Yield Transcript Labelling Kit (Affymetrix).
• Thaw all reagents and double stranded cDNA at room temperature.
• A master mix for each reaction tube was prepared at room temperature as 
follows:
10 pi DEPC treated sterile water 
4 pi (lOx) HY Reaction Buffer 
4 pi Biotin-labelled ribonucleotides 
4 pi DTT
4 pi RNase Inhibitor Mix 
2 pi T7 RNA Polymerase 
28 pi Total
• Add 28 pi of the master mix to each of the 12 pi cDNA previously prepared 
and mix by pipetting.
• Incubate reaction tubes at 37C° for 5 hours. Gently mix by tapping every hour.
• After the incubation, clean up reaction tubes or store to -80C°.
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Clean Up ofcRNA.
Note: The clean up process utilizes the Qiagen RNeasy Mini Kit.
• To the in vitro reaction tubes add the following:
60 pi DEPC treated sterile water 
350 pi RTL Buffer (with lOpl jS-mercaptoethanol/ml)
250 pi 100% ethanol.
• Mix samples by pipetting and apply them to the RNeasy mini columns.
• Spin columns at maximum speed for 15 seconds.
• Discard the flow-through from the collection tubes.
• Add 500 pi of RPE to each of the columns.
• Spin columns for 15 seconds at maximum speed.
• Discard the flow-through from the collection tubes and add 500 pi of RPE 
buffer.
• Spin columns for 2 minutes at maximum speed.
• Transfer columns to fresh tubes and spin for 1 minute at maximum speed.
• Transfer spin columns to new collection tubes in order to prevent any possible 
RPE carry over.
• Elute cRNA by placing 50 pi of DEPC treated sterile water on the middle of 
the membrane of the spin column and incubate at room temperature for 4 
minutes.
• Spin columns for 1 minute at maximum speed.
• Take the eluate and re-apply it to the same spin column. Incubate columns for 
4 minute at room temperature.
• After the incubation period, spin columns for 1 minute at maximum speed.
• Collect cRNA and measure its quantity by UV spectrophotometry as described 
above.
cRNA Fragmentation.
Note: 25 pg of cRNA is required for fragmentation.
• Prepare the following master mix for each fragmentation reaction:
X pi cRNA (25 pg)
Y pi DEPC treated sterile water 
lOpl (5x) Fragmentation Buffer*
50 pi Total
• Incubate tubes at 94C° for 35 minutes in a heated block.
• After the incubation period, place tubes on ice and store at -80 C°.
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*(5X) FRAGMENTATION BUFFER
4 ml 1M Tris-acetate pH 8.1 (Trizma base. pH adjusted with glacial acetic acid.)
0.64 gr Magnesium acetate (Sigma)
0.98 gr Potassium acetate (Sigma)
DEPC treated sterile water to a total of 20 ml.
• Mix solutions thoroughly and filter through a 0.2 pm vacuum filter unit. Store 
at room temperature.
2.8 RT-PCR. Primers and PCR Programs.
• The following were placed in a microfuge tube:
X pi (1 pg) total RNA in DEPC treated sterile water
Y pi DEPC treated sterile water 
9 pi Total
• Mix the above gently by pipetting and incubated for 10 minutes at 70 C° in a 
PCR machine.
• Prepare a master mix per reaction tube on ice with the following reagents:
2 pi Primers (Random Hexamers)
4 pi (5x) First Strand Buffer 
2 pi DTT (0.1M)
1 pi dNTPs (lOmM)
9 pi Total
• Mix gently by pipetting and add 9 pi of master mix to each reaction tube.
• Incubate reaction tubes at 42 C° for 2 minutes in a heated block.
Superscript Double Stranded 
cDNA Synthesis Kit 
(Invitrogen)
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• After 2 minutes, add 1 pi of Superscript II Reverse Transcriptase (200 U/pl) in 
each reaction tube.
• Incubate tubes for 1 hour at 42C°.
• Inactivate enzyme at 70C° for 10 minutes.
• Use 2 pi of cDNA for PCR by utilising primer sequences and Annealing 
Temperatures as given in Table 2.1
Gene Primer Sequence Annealing
Temperature
PCR
Cycles
Product 
Size (bp)
ADRB 5’ AAGAATAAGGCCCGAGTGGT 3’ 
5’ GTCTTGAGGGCTTTGTGCTC 3’
59 °C 27 2 1 2
ALS 5’ ACTCAGTTTGGGCAACAACC 3’ 
5’ CGGTCCAGGTAGAGCTTCTG 3’
59 #C 27 168
CLDN1 5’ GATGTGGATGGCTGTCATTG 3’ 
5’ CGTGGTGTTGGGTAAGAGGT 3’
59 °C 27 250
GLP2 5’ AAGCAGCCAGAAGCAGACTC 3’ 
5’ TAAGACCGTCCTGGAGCACT 3’
58 °C 27 228
NUPR1 5’ TCTGCTTCTTGCTCCCATCT 3’ 
5* CAGACCACAGACACCACACC 3’
60 °C 27 155
TBL3 5’CACAGCCTCTGCTGATGGTA 3’ 
5’ CTTCTGCCTGCTCAGCTTCT 3’
59 °C 27 317
VDR 5’ GAGGTGTCTGAAGCCTGGAG 3’ 
5’ ACCTGCTTTCCTGGGTAGGT 3’
59 °C 27 155
P21 5’ CCCGTGGACAGTGAGCAGT 3’
5» GGGCACTTCAGGGTTTTCTCT 3’
59 °C 30 450
HPRT 5* GTCAAGGGCATATCCAA 3* 
5’CGTGCTGGATTACATTAAAGCA 3’
57 °C 35 350
Table.2.1. Primer sequence, PCR annealing temperatures, PCR cycles and product 
sizes for RT-PCRs.
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Chapter 3 — In Vivo Characterisation of a BLG-Smad4 Transgenic 
Line in the Mammary Gland.
3.1 Introduction.
3.1.1 TGF-p and Breast Cancer. A Dual Role.
TGF-ps are characterised as tumour suppressors in the mammary gland based on the 
following observations; TGF-ps are expressed during all stages of mammary 
development except lactation (Robinson 1991), and they show potent growth 
inhibitory effects on mammary epithelial cells both in vivo and in vitro (Hosobuchi 
1989). TGF-p appears to regulate normal ductal and alveolar development in the 
mammary gland (Pierce 1993, Jhappan 1993). It has also been demonstrated that 
many breast cancer cell lines exhibited absent or decreased TGF-p responsiveness 
(Reiss 1997). Finally, early premalignant breast lesions showed a decreased 
expression of TGF-p type II receptors and therefore increased probability of an 
invasive disease (Gobbi 1999).
The growth inhibition by TGF-p on epithelial cells has been characterised extensively 
and, depending on the cell system and experiments, has been shown to be 
concomitant with apoptosis (Rotello 1991, Bursch 1993). Some of TGF-p actions are 
the induction of CD95/Fas (Ashley 1998), down-regulation of c-Myc and up- 
regulation of p27  (Kim 1998), down regulation of NF-kB (Azuma 1999), down 
regulation of Bcl-2 (Tsukada 1995), down regulation of p21 and increased expression 
of p53 (Yan and Sage 1998), induction of Bax (Teramonto 1998), induction of G1 
arrest (Motyl 1998) and practically every other permutation of genes involved in cell 
cycle or cell death. Thus, TGF-P- mediated growth inhibition and apoptosis can be 
correlated with a general function of a tumour suppressor within this tissue.
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However, contrary to the above, it has also been demonstrated that TGF-ps can have 
oncogenic activities under certain circumstances. During multistage tumorigenesis, 
TGF-p growth inhibitory and apoptotic effects are lost, frequently by subversion of 
the normal signaling pathway due to activation of other signaling molecules including 
PI3K and Ras (Derynck 2001, Akhurst 2001, Wakefield 2002). Moreover, as tumour 
cell progress, they secrete ever-increasing quantities of TGF-p 1 and become more 
migratory and invasive (Derynck 2001, Akhurst 2001, Wakefield 2002, Oft 2002).
3.1.2 Smad4 and Apoptosis.
Smad4 or DPC4 (Deleted in Pancreatic Carcinoma, locus 4) plays a key role in TGF-/3 
signaling thereafter participates in the regulation of cell proliferation, differentiation 
and apoptosis. It has been characterised as a candidate tumor suppressor gene due to 
its frequent inactivation/mutation in pancreatic and colorectal cancers (Hahn 1996, 
Riggins 1996). Results from several studies have suggested that defects in Smad4 
expression play a significant role in the malignant progression of tumors (Wilentz 
2000, Takaku 1998) while expression of Smad4 in Smad4-defective tumor cell lines 
has been shown to restore TGF- /3 signaling and induce cell cycle arrest and apoptosis 
(Dai 1999a). In addition to Smad4’s antiproliferating activity it has been demonstrated 
that expression of Smad4 in tumor cell lines inhibits expression of the vascular 
endothelial growth factor (VEGF) and enhance the levels of the angiogenesis inhibitor 
thrombospondin-1 (TSP-1), causing cells to switch from potentially angiogenic to 
antiangiogenic both in vivo and in vitro (Schwarte-Waldhoff 1999). Further evidence 
for Smad4 significance has been demonstrated in the following studies. Expression of 
Smad4 in Smad4-null breast carcinoma cell lines restored TGF-/3 signaling and 
showed reduced efficiency of colony formation in soft agar and a modest reduction of 
cells in the S phase without induction of apoptosis under normal culture conditions. 
Interestingly, induction of apoptosis by Smad4 expression was demonstrated in cell 
suspension in a process termed anoikis (Ramachandra 2002). In another paper, Yoo 
(2003), demonstrated that GADD45b is a positive mediator of TGF-/3 induce 
apoptosis and that Smad2, 3 and Smad4 are responsible for its activation. In a paper
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by Narula (2002), conditional overexpression of Smad4 in the testis demonstrated 
amongst other apoptosis of germ cells and spermatogenic arrest illustrating once more 
Smad4 as an important regulator of apoptosis. Takaku (1998) demonstrated that 
Smad4/APC double mutant heterozygote mice developed tumours while single 
heterozygotes did not. Finally, Lee (2001) demonstrated that decreased Smad4 mRNA 
expression is associated with defective TGF-p response and growth inhibition and 
that activation ofPAI-1 by TGF-P is Smad4 dependent.
3.1.3 The Transgenic Approach.
In order to investigate the role of Smad4 in mammary epithelial cell apoptosis it 
seemed appropriate to attempt a transgenic approach to the problem. I decided to 
address this question via tissue specific over expression of the human Smad4 gene 
through a transgenic model, termed BLG-Smad4. These mice express higher than 
normal levels of human Smad4 protein during mammary gland lactation and 
involution and were previously constructed in Edinburgh by other workers. To 
achieve over expression of Smad4 in mouse mammary epithelial cells we chose the 
BLG (beta-lactoglobulin gene) promoter.
The BLG gene has been extensively characterised and its promoter has been 
successfully used in the past to target gene expression to secretory epithelial cells of 
the mammary gland (Whitelaw 1992, Farini 1995, Clark 1992). The gene encoding 
the milk protein BLG in sheep is expressed in the mammary gland in a tissue-specific 
manner during pregnancy and lactation. Expression is induced mid-way through 
pregnancy, peaks during lactation and begins to decline at the onset of involution. The 
unmodified sheep gene behaves appropriately in transgenic mice, and it has been 
shown that many of the cis-acting elements that mediate this pattern of expression are 
located in the proximal 400bp of the promoter (Clark 1998). Expression patterns of 
the BLG are also well characterised and it has been demonstrated that BLG-driven 
transcription is correctly initiated in mice and that BLG-driven synthesis is restricted 
to the secretory epithelial cells of the mammary gland (Harris 1991). The BLG-
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Smad4 transgene vector used to generate our transgenic mice is illustrated in Figure 
3.1.
pBS-BLG-Smad4 
9433 bp
SV40 Origin BLG promoter Flag Tag SV40 Poly A Tail
Smad4
Figure 3.1 The complete transgene vector of the ovine beta-lactoglobulin promoter 
upstream of a human FL AG-tagged human Smad4.
3.1.3 Aims.
The hypothesis that Smad4 is an essential component of the initiation of epithelial 
apoptosis and thereby in the normal involution of the gland implies that over­
expression of Smad4, either before or during this period, “may lead to acceleration in 
the involution programme”. In this part of the project I chose to identify any possible 
alterations in mammary epithelial contribution during involution by histological 
comparison of BLG-Smad4 mice against wild types. Levels of apoptosis were 
analysed by performing TUNEL analysis and finally, molecular targets were analysed 
through Western blotting in order to identify any possible alterations in their 
expression following Smad4 over expression.
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3.2 Results
3.2.1 Time points and requirements.
All samples used in the following experiments were generated from the same cohort. 
Mice were genotyped by PCR (chapter 2) for the presence of a part of the BLG- 
Smad4 construct and named BLG-Smad4 (experimentals) while wild type littermates 
were used as controls. In order to minimize any alterations in mammary gland stimuli, 
all mothers were allowed to suckle 6-8 pups for 10 days (defined as day 10 of 
lactation). Involution was then forced by the removal of pups from the mother. Time 
points included daylO lactation and day 2, 3 and 6 of involution.
3.2.2 BLG promoter expresses human Smad4 in the murine mammary gland 
throughout involution.
Mammary tissue from our breeder mice was subjected to anti-FLAG western blot 
analysis, in order to determine expression of the transgene. The FLAG-tagged human 
Smad4 transgene has a predicted size of 60-70 kD and it was shown to be 
constitutively expressed in the mammary gland throughout involution exclusively in 
mice carrying the BLG promoter (Figure 3.2).
10lac 2 inv 3 inv 6 inv
wt Smad4 wt Smad4 wt Smad4 wt Smad4
FLAG-tagged human
Figure 3.2. Western blot shows expression of the FLAG-tagged human Smad4 
transgene protein only in the EK mice which are positive by PCR for the presence of 
the BLG promoter. The FLAG-tagged human Smad4 is about 60-70 kD and is present 
throughout lactation and involution (20 pg protein loaded per well).
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3.2.3 Over expression of Smad4 accelerates involution of mammary epithelial 
cells.
To investigate any possible alterations in the contribution of epithelial cells in the 
mammary gland during lactation and involution between BLG-Smad4 and wild type 
animals, a histological phenotypic analysis was undertaken by sectioning and staining 
with hematoxylin- and -eosin (H&E). The number of each genotype for each 
timepoint analysed was at least 3. Following our observation regarding FLAG-tagged 
transgene expression from day 10 of lactation up to day 6  Involution, we generated 
sections from day 10 Lactation and day 2, 3, 6  Involution. Figure 3.3 shows 
representative glands from BLG-Smad4 mice (A, C, E, G) and wild type (B, D, F, H) 
mice.
At day 10 of lactation, the majority of the gland was composed of alveoli lined by 
epithelial cells that secrete milk components into the alveolar lumina. No phenotypic 
differences were detected between BLG-Smad4 (Figure 3.3A) and wild type (Figure 
3.3B) mice at this stage. Furthermore, no differences were observed in the ability of 
BLG-Smad4 and wild type mice to feed and maintain their litters.
Forty-eight hours following removal of the pups (day 2 of involution), wild type 
glands have begun to show the characteristic degradation of the gland with milk ducts 
losing their tightly expanded appearance and cell death resulting in epithelial cell loss 
(Figure 3.3 C and D). In transgenic mice this process appears to be accelerated and 
many of the ductal structures contain sloughed apoptotic fragments associated with 
this process.
By day 3 of involution, the BLG-Smad4 glands have undergone extensive 
remodelling characterised by collapsing alveoli structures and a significant increase in 
the amount of fat indicating a mammary phenotype close to its virgin state (Figure 3.3 
E and F). Wild type glands in contrast, show somewhat slower involution. As shown 
in Figure 3.3 F the gland still possesses intact alveolar structures and significantly 
fewer fat cells compared to BLG-Smad4 mice. At this point wild type glands are 
similar to BLG-Smad4 glands at their second day of involution.
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Finally, by day 6  of involution in both wild type and transgenic mice glands have 
nearly all collapsed. Glands have been remodelled and are mainly occupied by fat 
cells and only occasional epithelial cords and ducts can be seen (Figure 3.3 G, H).
To quantify the degree of involution occurring in the mammary over expressing 
Smad4 mice compared to wild types, the area of the gland occupied by fat was 
measured as previously described (Chapman 1999) and is shown in Figure 3.4. At the 
tenth day of lactation less than 5% of the area of the gland was occupied by fat cells in 
both Smad4 and wild type animals. By day 2 and 3 of involution, Smad4 animals 
have a significantly higher fat cell contribution when compared to wild types. 
Specifically, at day 2, Smad4 glands showed 28% fat cell composition while wild 
types showed 17%. At day 3 of involution, Smad4 glands had a fat cell contribution 
of 47% compared to 33% in wild types. Taken together, these results show an 
accelerated involution in mice over expressing human Smad4 protein. Finally at day 
6 , both glands have remodelled to resemble to a virgin like state characterised by a 
high fat cell contribution. At this point the programme of involution in wild type 
glands has apparently “caught up” with the Smad4 transgenics probably during day 4 
and 5 of involution.
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Day 2 
Involution
Day 3 
Involution
H
Day 6 
Involution
Figure 3.3. Accelerated involution in BLG-Smad4 mammary glands (A, C, E, G) 
compared to wild types (B, D, F, G). Mammary glands at day 10 of lactation (A,B); 
Day 2 Involution (C,D); Day 3 Involution (E,F); Day 6 Involution (G,H). 
Microscope scale: X40. Scale bar 100pm.
Day 10 
Lactation
Smad4
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Figure 3.4. Fat contribution in BLG-Smad4 mice compared to wild types at 
day 10 lactation and 2, 3 and 6  of involution. BLG-Smad4 mice show 
significant accelerated reappearance of fat at day 2 and 3 of involution when 
compared to wild types. Each bar represents the data collected from at least 3 
mice. BLG-Smad4=open bars, Wild types=solid bars.dl01ac=day 10 lactation, 
d2, 3, 6  Inv=day 2, 3, 6  Involution respectively. Error bars represent standard 
error of the mean. *p<0.05 Mann-Whitney U test. (Lac)- lactation, (inv)- 
Involution
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3.2.4 Over expression of Smad4 increases apoptosis in mammary epithelial 
cells.
During mammary gland involution, epithelial cells undergo apoptosis and are shed 
from the epithelial wall (Strange 1995). In this way the gland resembles a virgin like 
stage composed of adipocytes. Following my observation regarding accelerated 
involution at day 2 and 3 in the Smad4 transgenics, I decided to investigate whether 
these changes were caused by increased apoptosis. Apoptosis was measured by 
morphological criteria, such as condensed chromatin (Figure 3.5), and also by 
TUNEL analysis of DNA strand breaks (Figure 3.6).
Morphological assessment of mammary epithelial cell apoptosis at day 2 and 3 of 
involution showed a significant increase of apoptosis in the BLG-Smad4 mice 
compared to wild types (p<0.05) (Figure 3.5).
This increase in apoptosis in the BLG-Smad4 mice was confirmed by TUNEL 
analysis (Figure 3.6). A significant increase in epithelial apoptosis was seen at day 2 
and day 3 of involution in Smad4 transgenic mice when compared to wild types. 
Specifically, at day 2 Smad4 mice showed a 3% increase in apoptosis compared to 
wild types while at day 3 this increase is 4.8%. At day 6  of involution, both transgenic 
and wild type glands showed similar levels of apoptosis.
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Figure 3.5. Acceleration of epithelial apoptotic cells in BLG-Smad4 mice 
mammary glands. (A) Morphological assessment of apoptotic epithelial cells at 
Day 3 of Involution. Arrows indicate apoptotic cells. (B) Graph represents 
apoptotic data from day 2 and 3 of involution. BLG-Smad4 mice shows 
significant increased levels of apoptotic cells when compared to wild types at 
both day 2 and 3 of involution. BLG-Smad4=open bars, Wild types=solid bars. 
Each bar represents the mean of data collected from at least three mice. 
N=number of mice used.d2 Inv and d3 Inv=day 2, 3 involution respectively. 
Error bars represent standard error of the mean *p<0.05. Scale bar 10pm.
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BLG-SMAD4 WT
d3lnv d6lnvd2lnv
Figure 3.6. Acceleration of epithelial apoptosis in the mammary gland. A) 
Photographs (BLG-Smad4) and (wild type) represent TUNEL slides from day 3 
involuting mice. Arrows indicate apoptotic cells. B) Graph illustrates apoptosis 
as counted by TUNEL. Each bar represents the mean of data collected from at 
least 3 mice. Significant increased levels of apoptosis can been seen at day 2 
and 3 of involution in the BLG-Smad4 mice compared to wild types. BLG- 
Smad4=open bars, Wild types=solid bars. d2, 3, 6 Inv=Day 2, 3, 6 involution 
respectively. Error bars represent standard error of the mean. *p<0.05 Mann- 
Whitney U test. Scale bar 10pm.
3.2.5 Molecular analysis of Stat3 and Stat5a in an over expressing Smad4 
mammary gland environment.
It is well known that Stat3 and Stat5a are important mediators of mammary gland 
development. Stat5a was originally described as a regulator of milk protein gene 
expression and was subsequently shown to be essential for mammary development 
and lactogenesis (Liu 1996). In contrast, Stat3 is an essential mediator of apoptosis 
and post-lactational regression (Philip 1996). Furthermore, it has been shown that 
Smads and Stats can act in synergy by binding to the transcriptional co-activator p300
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(see also 4.1.3) (Nakashima 1999) and that over expression of TGF-a results in 
deregulation of both Stat3 and Stat5a in the involuting mammary gland (Schroeder 
2001). Taking into account the above, I investigated the levels of both proteins by 
Western blot analysis (Figure 3.7). Absolute levels of Stat3 were assessed as well as 
levels of Stat3 relative to actin.
Stat3 protein was detected at all time points investigated (Day 10 lactation and day 2, 
3 and 6  of involution). At day 10 of lactation there was slightly less Stat3 in the BLG- 
Smad4 transgenics compared to wild types. At day 2 of involution levels of Stat3 are 
elevated compared to day 10 of lactation, with higher levels in the BLG-Smad4 
transgenics compared to wild types. At day 3 of involution Stat3 levels are down 
regulated in the BLG-Smad4 transgenics compared to wild types. At day 6  of 
involution, Stat3 levels appear equal in the two genotypes. Quantification of these 
results relative to actin levels indicate that the above results are not confounded by 
changes in cellular composition, which was a possibility given that BLG-Smad4 mice 
have less epithelial cells compared to wild types.
Stat5a levels where also measured and again quantified against actin levels (Figure 
3.7). Stat5a was again detected throughout involution. High and equal levels of Stat5a 
were present at day 10 of lactation. During involution Stat5a levels dropped 
significantly, however, Stat5a remained relatively higher in the BLG-Smad4 
transgenics compared to controls of both day 2 and 3 of involution. Quantification of 
these results relative to actin indicates that Stat5a is induced in BLG-Smad4 mice on a 
“per cell” basis compared to wild types at both day 2 and 3 of involution.
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Figure 3.7. Molecular changes during involution by western blot. lOjig protein/lane for 
actin and 20 jig for Stat3 and Stat5a at day 10 lactation (lac) and day 2, 3 and 6 of 
involution (inv). Left graph: densitometry analysis from three independent mice, mean 
calculated as absolute densitometric values for each blot. Right graph: values relative to 
actin calculated as a proportion of the mean (hence no error bars are included). The 
Stat3 antibody gives a 92kDa product while Stat5a and actin 85 kD and 51kD 
respectively. White bars represents Smad4 and black bars are wild type.
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3.2.6 Over expression of Smad4 increases expression of p27Kipl and is not 
influencing expression of p21 and Bax.
In order to investigate further the accelerated involution observed in Smad4 mice I 
analysed via Western blotting a number of known apoptosis regulatory factors, which 
have all been demonstrated to influence mammary epithelial cell apoptosis.
It has been shown that the cyclin-dependent kinase inhibitor p27Kipl is required for 
normal mammary gland morphogenesis and function (Muraoka 2001) through its 
ability to regulate cell cycle progression. More specifically, loss of one p27 allele 
decreases apoptosis and delays involution of the mammary gland compared to wild 
types. As with Stat3 and Stat5a, I assessed p27Kipl levels independently and relevant 
to actin levels. Levels of p27 were detectable at all time points (Figure 3.8), with 
similar levels at day 10 of lactation and at day 6 of involution in both genotypes. At 
day 2 and day 3 of involution levels of p27Kipl were increased in the BLG-Smad4 
transgenics.
An important apoptotic signal in mammary epithelial cells involution is Bax (Adams 
and Cory 1998). Western blot analysis showed a steady appearance of Bax from 10 
lactation up to day 6 of involution, however with no major differences between the 
BLG-Smad4 mice and wild types (Figure 3.8). Quantification of these results relative 
to actin revealed an increase of Bax in the Smad4 transgenics compared to wild types 
at the third day of involution.
Another important cyclin-dependent kinase inhibitor whose mRNA levels have been 
demonstrated to increase during mammary gland involution is p21WaJ1 (Jerry 1998). 
Smad3 and Smad4 have been shown to up regulate transcription of the p21W a gene 
by cooperating with Spl (Pardali 2000). However, low levels of p21Wa*1 were detected 
by Western blot analysis and no increase was observed in the Smad4 transgenics 
(Figure 3.9A). P21Wa^  levels were also investigated via semi-quantitative RT-PCR 
from day 3 involuting mice (Figure 3.9B). Very low and equal levels of p21Wc^  were 
observed in the BLG-Smad4 transgenics as well as in the wild type animals. P21Wa*1
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Figure 3.8. Molecular changes during involution by Western blot. 10pg protein/lane 
for Bax, 20pg protein/lane for P27 at day 10 lactation (lac) and day 2, 3 and 6 of 
involution (Inv). Left graph: densitometry analysis from 3 independent mice. Mean 
calculated as absolute densitometric values for each blot. Right graph values relative 
to actin calculated as a proportion of the mean. Bax antibody produces a 23 kD 
product, p27 shows as a 27kD product.
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Figure 3.9. A) Western Blot analysis for p21. 40pg of protein for day 10 lactation and 
day 2, 3 and 6 of involution. PC=Positive Control for p21 western blot is a DAP 
Kinase Knockout protein sample. Low levels of p21 were detected. B) RT-PCR 
analysis for p21 from day 3 involuting mice. Low expression of p21 mRNA in both 
BLG-Smad4 and wild type mice. HPRT used as an amplification control. C) P21 
Immunohistochemistry. P21 was absent in the BLG-Smad4 mice. Black arrows 
indicate cells stained positive for p21. PC*=Positive control for p21 was a Stat3 
Knockout.
p21
HPRT
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3.2.7 BLG promoter is not expressed in mammary epithelial cell cultures.
In order to overcome problems arising from the examination of a mixed population of 
cells within a dynamic tissue such as the mammary gland I next decided to perform 
primary mammary cell cultures. In this way I aimed to overcome this problem by 
creating a more controlled environment where I could investigate the contribution of 
Smad4 to cell cycle progression, apoptosis and possibly cell attachment. Primary 
mammary cultures were performed with glands taken from 15-17 day pregnant mice 
(Figure 3.10 A). RNA was extracted from 50-60% confluent epithelial cells and RT- 
PCR performed for the presence of the BLG-Smad4 construct. Unfortunately, RT- 
PCR revealed an absence of expression of the transgene indicating that the BLG 
promoter was not functioning in mammary explant cultures.
Figure 3.10. A) Primary mammary epithelial cell culture B) RT-PCR for the presence 
of BLG-Smad4 transgene. L=Ladder. Lanes 1-2=Unsuccessful amplification for the 
BLG-Smad4 transgene from Smad4 and WT cultures respectively. Lanes 3-4=HPRT 
amplification from the same samples as in lanes 1 and 2. C=Control for the BLG- 
Smad4 transgene. Control RNA has extracted from in vivo Smad4 transgenic mice.
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3.3 Discussion.
Here I report the analysis of a transgenic strain over expressing Smad4 within the 
mammary gland. Tissue specific Smad4 expression was driven by the BLG promoter, 
to deliver expression during mid-pregnancy, lactation and involution. I have 
confirmed the expression of human flag tagged Smad4 transgene by western blot 
analysis.
Smad4 has been characterised as a tumour suppressor gene due to its ability to arrest 
cell division and promote apoptosis (Dai 1999). In agreement with this observation 
BLG-Smad4 mice exhibited accelerated epithelial cell death at day 2 and 3 of 
involution. The level of difference in epithelial cell contribution in the gland was 
measured indirectly by measuring fat contribution (Chapman 1999). At day 2 
involution BLG-Smad4 mice showed an 1.6 fold increase in the level o f cell death 
compared to wild types whilst at day 3 this increase was 1.4 fold. At day 6 of 
involution the majority of the gland has been remodelled to resemble a virgin like 
state.
In order to investigate whether induced apoptosis is responsible for the accelerated 
involution I scored apoptosis by the criterion of chromatin condensation and TUNEL 
(Li 1997). These two approaches yielded similar data indicating a significant increase 
in apoptosis at both day2 and day3 of involution in the BLG-Smad4 mice compared to 
wild types.
Based on the phenotypic differences exhibited by BLG-Smad4 mice I decided to 
molecularly investigate a number of targets with which Smad4 has been demonstrated 
to interact.
It is known that both Smad4 and Stat3 induce apoptosis (Dai 1999, Philip 1996) and 
that are bridged by the transcriptional co-activator p300 (Nakashima 1999). Previous 
studies have shown that Stat3 deficiency in the mammary gland resulted in delayed 
involution with decreasing levels of apoptosis (Chapman 1999). Here, western blot 
analysis revealed an up-regulation of Stat3 in the BLG-Smad4 transgenic mice at
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day2 of involution compared to wild types. This induction o f Stat3 becomes event 
greater after quantification relevant to actin. Contrary, at day3 of involution the 
opposite scenario takes place. Stat3 shows a down regulation in the BLG-Smad4 
transgenic animals when compared to controls. It has been demonstrated that Stat3 
becomes activated at the start of involution (Li 1997). This activation has been 
enhanced at day 2 involution in the over expressing Smad4 mice indicating a 
mechanism where a co-operation between Smad4-Stat3 may promote apoptosis in 
mammary epithelial cells. However, down regulation of Stat3 in the over expressing 
Smad4 mice may indicate a possible compensatory mechanism where Stat3 tries to 
balance this accelerated cell death observed during day 3 involution. Down regulation 
of Stat3 at day 3 of involution in BLG-Smad4 mice indicates a reciprocal relationship 
between Stat3 and Smad4 and may go someway to explain the observed phenotype at 
day 6 of involution.
Stat5a is a tyrosine phosphorylated signaling protein that lies downstream of the 
prolactin-signaling pathway in normal mammary epithelial cells (Hennighausen 
1997a). It has been demonstrated that Stat5a’s physiological role is to promote cell 
survival and its loss results in increased apoptosis during mammary gland involution 
(Humphreys and Hennighausen 1999). Here I report a steady induction of Stat5a in 
the BLG-Smad4 mice compared to controls throughout involution. Induction of 
Stat5a in the BLG-Smad4 mice possibly reflects the induction of a cell defense 
mechanism towards survival or may reflect a dynamic balance operating in the 
mammary which can restore a normal phenotype at day 6 of involution in the BLG- 
Smad4 glands.
The Bcl-2 gene family regulates tissue development and homeostasis through the 
interplay of survival and death factors (Schorr 1999). Bax is a member of the Bcl-2 
family, levels of which had been shown to increase during lactation and remain high 
during involution (Merto 1997). Bax levels were investigated by Western blotting and 
in agreement with Merto’s (1997) paper, I found high and equal levels throughout 
involution in wild type mice and also in the BLG-Smad4. Quantification relevant to 
actin however, revealed an increase of Bax levels in the BLG-Smad4 transgenics
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compared to controls at day 3 of involution. These data suggest once more the 
involvement of Bax in apoptosis during involution.
To investigate further the molecular events underlying the accelerated involution in 
the BLG-Smad4 transgenic mice, I analysed the expression levels o f the cell cycle 
regulators p 2 1 Wa*1 and p27Kipl which are known to play important roles in cell cycle 
progression (Sherr and Roberts 1999). The p21Wa^  protein has been shown to interact 
with Smad3 and Smad4 through the cooperation with Spl (Pardali 2000). Low levels 
of p21Wafl were detected by Western blot analysis and no increase was observed in the 
Smad4 transgenics. Similarly, low levels of P21Wafl were detected by RT-PCR 
analysis at day 3 involution, indicating an independency of mammary epithelial cell 
apoptosis from this molecule. P21Wa*1 was not detected by immunohistochemical 
analysis in either genotype. Based on the above results I therefore conclude that in my 
model of study Smad-dependent expression of the P21Wa^  is absent.
Another important cyclin-dependent kinase inhibitor studied was p27Kipl. P27Kipl has 
been shown to be important in mouse mammary gland morphogenesis and function 
(Muraoka 2001). In the same paper it has been demonstrated that haploidp27Kipl gene 
inactivation causes amongst others increased proliferation and delayed involution. 
Cooperation between TGF-p/Smads and p27Kipl has been shown to exist through 
Jabl, a co-activator of c-Jun. Jabl induces degradation of both p27Kipl and Smad4 
and antagonises TGF-beta function by inducing degradation of Smad4 through a 
distinct degradation pathway (Wan 2002). P27Kipl levels were analysed through 
western blotting and found to be significantly increased at day 2 and 3 of involution. 
The data presented herein support the notion that p27Kipl levels regulate proliferation 
and comes in agreement with the accelerated involution as well as increased apoptosis 
observed at the same time points.
In an attempt to simplify the analysis I decided to also investigate Smad4’s over 
expression by using primary mammary epithelial cell cultures. However, RT-PCR 
analysis indicated that expression of the BLG-Smad4 construct failed in vitro.
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In conclusion, over expression of Smad4 driven by the BLG promoter in the 
mammary gland accelerates involution of epithelial cells by inducing apoptosis at day 
2 and 3 o f involution through a p27Kipl mechanism which is independent of p21WafI. 
Targets such as Stat3 and Stat5a showed a differential expression at day3 of 
involution in our transgenic mice compared to wild types, indicating once more the 
interplay between the Smad and Stat pathway. Considering the numerous potential 
targets of Smad signaling further studies are clearly necessary both in vivo and in vitro 
in order to address whether any other mechanisms are responsible for this acceleration 
of involution. To directly approach this question, I adopted a microarray approach 
described in the following chapter.
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Chapter 4- Microarray Analysis of Day 3 involuting mammary glands 
in a Smad4 over expressing environment.
4.1 Introduction
4.1.1 Microarray Analysis of Smad4.
The use of microarray technologies to monitor gene expression in model organisms, cell 
lines, and human tissues has become an important part of biological research over the last 
several years. Teasing apart biochemical pathways, identifying genes responsible for a 
particular phenotype, and assessing the effect of a drug compound on the expression 
levels of any number of genes have all benefited from expression array technology. 
Taking into account the usefulness of this technology, I decided to undertake a mouse 
DNA microarray approach.
It has been demonstrated that TGF-/3 and Smads regulate, and are regulated by, a vast 
number of biological pathways. My goal in this part of the project was to identify, 
categorize and link to known pathways, a number of genes whose expression is altered by 
Smad4. In this way I am aiming to gain a broader view of any possible alterations in gene 
expression caused by over expression of Smad4 in the mammary gland during involution.
Based upon the phenotypic and molecular differences presented in Chapter 3 ,1 decided to 
compare and analyze gene expression profiles of BLG-Smad4 transgenic mice against 
wild types from day 3 involution. Furthermore, in this chapter I will discuss briefly 
Affymetrix technology and describe key issues that relate to the preprocessing and 
analysis of data.
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4.1.2 Affymetrix Technology.
There are several publications discussing the fundamentals of the oligonucleotide 
expression microarray technology (Lockhart 1996). However, for the purpose of this 
chapter it will be useful to review some of the basics of this technology. Affymetrix chips 
are microscope slides that contain a series of samples (DNA, RNA, protein tissue). As 
mentioned above, we have utilised cDNA printed slides in order to check expression of 
genes in this level. Each gene is represented on the chip as multiple probe sets each 
consisting of 10-25 oligonucleotide pairs. The oligonucleotide pair (probe pair) is 
composed by a series of oligonucleotides which are unique to a gene or show less 
similarity to other genes. These oligonucleotides are chosen as perfect matches (PM) (i.e. 
perfectly complementary to the mRNA of that gene). In addition, Affymetrix has 
generated the same oligonucleotide probes, which are identical to the PM 
oligonucleotides except for the central position 13, where one nucleotide has been 
changed to its complementary nucleotide. This probe set is termed Mismatch oligos 
(MM) and their aim is to detect non-specific and background hybridizations. Probes are 
designed within 500 base pairs of the 3’ end of each gene in order to hybridize uniquely 
in the same, predetermined hybridization conditions.
RNA is extracted, converted to cDNA, labelled with biotin and fragmented (see Materials 
and Methods), before the actual hybridization takes place. Biotin labelled mRNA will 
hybridise to its corresponding perfect match. The technology is based on the simple 
hypothesis that the greater the abundance of the gene in the sample mRNA the more 
expression signal and the other way around. The biotin labelled RNA is stained with 
phycoerythrin conjugated streptavidin after washing and scanned with a Gene array 
scanner. A grid is automatically laid over the array image and the intensities of each 
probe pair are used to calculate expression measurements with the Affymetrix Microarray 
suite.
Analysis generates qualitative and quantitative values from one gene expression 
experiment and provides initial data required to perform comparisons between
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experiments. A quantitative value, a Detection call, indicates whether a transcript is 
reliably detected (Present) or not detected (Absent) in the array. Based on the Present- 
Absent calls, preprocessing, normalization and statistical analysis are the three main steps 
before a reliable indication for altered gene expression. Figure 4.1 illustrates the 
representative approach which I followed for performing the above steps.
4.1.3 Normalization.
Affymetrix oligonucleotide arrays simultaneously measure the abundances of thousands 
of mRNAs in biological samples. There are many sources of systematic variation in 
microarray experiments that affect gene expression levels. To reliably compare data from 
multiple chips we need to minimize non biological differences that may exist. Typically, 
the first transformation applied to expression data, referred to as normalization, adjusts 
the individual hybridization intensities to balance them appropriately so that meaningful 
biological comparisons can be made (Yang 2001). There are two broad characterizations 
used for the type of variation that can be seen when comparing arrays: interesting 
variation (true biological variations in expression levels of genes between control and 
experimental arrays) and obscuring variations. Examples of obscuring variations arise 
due to differences in sample preparation (for example labeling differences), production of 
the arrays and preprocessing of the arrays (for example scanner differences) (Hartemink 
2001). The purpose of normalization is to deal with obscuring variations and bring the 
data from the different experiments onto a level baseline field. Depending on the 
normalization method of choice, statistical analysis could be directed towards parametric 
or non-parametric mode. For the purpose of this analysis I chose to normalize by logging 
the data and thus create a normally distributed (linear) shape data. Linear data can be 
analyzed by means of parametric tests (in this analysis t-test ) and will be explained in 
more detail below.
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Data from image analysis
____________________________ i __________________________________
Filter Bad Data | | Check Affy Controls
i
Log Data (Normalization)
1r
t-test for significant results
i
Calculate log Averages within genes
T
Calculate Log Ratios 
▼
List of Significant genes
Figure 4.1. A representative method for preprocessing (filtering), normalizing and 
statistically analyzing Affymetrix data.
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4.2 Results.
4.2.1 RNA preparation and Affymetrix chip.
Samples collected from day 3 involuting mice. Samples were subjected to RNA 
extraction and cleaning, double stranded RNA production, nucleotide labeling (one color) 
and fragmentation following all procedures and materials as written in Chapter 2 (2.7.3).
Labeled RNA samples were supplied to University of Wales College of Medicine 
Affymetrix facility where 3 Affymetrix U74v2 chips used for each genotype (6 chips in 
total). Chips were hybridized and analyzed with Affymetrix Gene Chip Hybridization and 
Analysis system.
4.2.2 Affymetrix gene controls and run consistency between chips.
Affymetrix chips also contain various mouse housekeeping genes as three probe sets. 
Each set is designed to the 5’ end, to the middle of the gene and the 3’ end respectively. 
In addition to mouse specific genes, spiked-in control probe sets exist originating from 
organisms such as E.Coli, Bacteriophage and B.Subtilis. Control gene sequences do 
possess signal intensity values despite their inability to show differential expression to 
mouse RNA. Reasons for this signal values are due to a number of systematic variations 
(labelling, scanner differences etc.) in microarray experiments that can affect measured 
gene expression levels. Signal values of gene controls provide a good indication for 
checking consistency of runs between different Affymetrix chips i.e. checking whether 
different chips possess the same error levels or not.
As stated above I utilized 6 Affymetrix chips in total. I therefore checked chip 
consistency by summing all signal intensity values from 67 control gene sequences that 
exist in the Affymetrix data sheet. Figure 4.2 illustrates the comparison of control gene
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errors between genes. From this graph I concluded that all experimental and wild type 
chips show similar levels of error signal intensities and only slightly altered levels of 
errors between the two groups. Similarity in the control error intensities indicated similar 
patterns of hybridization procedures for each chip, thereafter indicating that these chips 
could be used further for gene expression analysis.
Control Signal Values
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■  M  WT3 ExP 1 Exp 2 Exp 3 H  ■  _m i l l
Chips
Figure 4.2. Summation of signal intensities from control genes. Each bar represents a 
different chip. Experimental (Exp) and wild type (WT) chips have a similar level of error 
signal intensities between group chips as well as between groups.
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4.2.3 Data Filtering.
Affymetrix analysis generates qualitative and quantitative values from one gene 
expression experiment and provides initial data required to perform comparisons between 
experiments. A quantitative value, a detection call, indicates whether a transcript is 
reliably detected (Present) or not detected (Absent) in the array. The detection call is 
determined by comparing the Detection /7-value generated in the analysis against user- 
defined cut-offs. This cut-off by default is 0.015.
For the purpose of this data analysis I have filtered out ‘Absent’ calls as such that a 
transcript can be present at least once in the control and experimental pools respectively. 
Filtering drastically reduced the available data from 12000 transcripts to 5800. Absent 
calls reflects sequences which are not expressed either in the control or experimental 
samples and which are removed by the “Filtering” process. P27, a target which its protein 
was over expressed in the BLG-Smad4 mice at day 3 involution (Chapter 3) was 
identified as absent in its mRNA expression at the same time point. A result which 
indicates that p27 mRNA and protein expression levels have an expression time 
difference of at least one day.
4.2.4 Data Normalization and Linearity.
As discussed in 4.1.3 many sources of systematic variations exist in microarray 
experiments affecting each time gene expression levels differently. Normalization is the 
term used to describe the process of removing such variation (Yang 2001 ^ Normalization 
can also be thought of as an attempt to remove the non-biological influences on 
biological data. Removal of variations between microarray chip data brings the data from 
different experiments to a common baseline from which valuable and statistically correct 
comparisons can be made.
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For the purpose of data pre-processing (normalization) I have utilised a common way of 
data transformation; log transformation. Log transformation has several important effects 
on the data (Speed 2000), one of them being to decrease signal errors (in an absolute 
sense) as the signal expression values decrease by logging.
Additionally, log transformation serves microarray data from another important point of 
view. Log transformation makes data more symmetrical (linear), one of the important 
assumptions of normality. Furthermore, log transformation reduces the influence of a 
single measurement. Figure 4.3 illustrates a representative graph of the mean values of 
experimental chip data before and after log transformation.
Unacceptable Histogram
Acceptable Histogram
mean not normally distributed lofl2 m8an
Approximately Normally Distributed
Figure 4.3. Normalization of gene expression profile by log transformation. Two 
histograms of the same data. Left histogram contains the raw mean data of the 3 
experimental chips, and the right histogram the log-transformed data. Log-transformed 
data is clearly more normal like than the non-transformed data.
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4.2.5 Parametric Tests; T-Test and Significance Analysis of Microarrays (SAM).
Parametric statistics test the hypothesis that one or more treatments have no effect on the 
mean of a chosen variable. As mentioned earlier, these tests are based on the assumption 
that data is taken from a normally distributed population, a distributed population that can 
be created by logging the data.
For identifying differentially expressed genes I utilised the SAM (Significance Analysis 
of Microarrays) software (Tusher 2001). SAM is publicly available software and can be 
located at http://www-stat-class.stanford.edu/SAM/SAMServlet. SAM has been 
developed to identify differentially expressed genes which show significant changes 
between them by assimilating a set of gene-specific t tests. For achieving its purpose 
SAM assigns a score in each gene on the basis of its change in expression relative to the 
standard deviation of repeated measurements for that gene. Genes with scores above a 
specified threshold are considered significant. From the group of genes which have been 
characterised as significant, there is a number of genes which have been identified by 
chance; this is what termed as the False Discovery Rate (FDR). SAM estimates the FDR 
by identifying nonsense genes through analysing permutations of the measurements. The 
cut off threshold can be adjusted to identify smaller or larger sets of genes, and FDRs are 
calculated for each set.
5800 Present transcripts were applied to the SAM software according to designer’s 
instructions. After the software logged the data in the base of 2, differential analysis 
created a plot which is presented in Figure 4.4. This graph created a number of questions 
because it failed to identify any significant differentially expressed genes (should have 
appeared as coloured dots). Furthermore I observed that the distribution of dots were 
presented graphically as a mirror image of what a normal plot should be like, showing 
that the observed significant targets are less than the expected ones (see below).
In order to reduce the stringency of the statistical analysis I decided to use another 
parametric test, the Student’s t-test. The t-test assesses whether the means or medians (in
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our case the means) of two groups (experimental against control) are statistically different 
from each other. More specifically after logging the data I have checked for significant 
results between the two groups. To test for significance I have used a probability level of 
0.05 (acceptable false rate) in a two tail paired t-test. A paired t-test is very powerful in 
that it compares the same gene between two treatments within an experiment, and so, 
variations (outliers due to noise) in the baseline and experimental values between 
experiments are mitigated.
Figure 4.4. SAM plot analysis. SAM failed to identify any significant differentially 
expressed genes despite the various adjustments of the delta error area (dotted lines). 
Furthermore, the graph itself is presented as a mirror image of a normal SAM plot, 
showing that the observed significant targets are less then the expected ones.
Significant' 0 Delta 0 20334
Median # fa lse  significant: 1.00000 S A M  P l o t  Fold Change
E xpected
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Following log transformation and two tail paired t-test of 5800 transcripts with a 
probability level of 5% I have identified 114 targets as statistically significant potential 
targets. Although p=0.05 is significant in the context of experiments designed to evaluate 
small numbers of genes, a microarray experiment for 5800 genes would identify 290 
genes by chance (FDR). This data indicates that the observed significant targets are less 
than the expected ones and can therefore explain the failure to observe any significant 
altered gene expressions from the SAM analysis as well as the mirror image which 
presented in the same graph (Figure 4.4).
In order to find whether these targets show altered signal expression values I calculated 
their log averages between groups. For each target I calculated the log ratio of the two 
means (experimental/control) due to the fact that although true signal ratios provide an 
intuitive measure of expression changes, they have the disadvantage of treating up- and 
down-regulated genes differently. Genes up regulated by a factor of 2 have an expression 
ratio of 2, whereas those down regulated by the same factor have an expression ratio of (- 
0.5). I have used an alternative transformation of the ratio by logging in the base of 2, 
which has an advantage of producing a continuous spectrum of values and treating up- 
and down-regulated genes in a similar fashion.
4.2.6 Expression profile changes in Smad4 transgenic mice.
I have utilized DNA microarrays to analyze gene expression profiles of human Smad4 
over expressing mouse in mammary epithelial cells. Smad4 over expressing epithelial 
cells have been compared to wild types. All samples have been harvested from mice at 
their 3rd day of involution. The Affymetrix gene chip used is the U74v2 consisting of 
12488 transcripts. Following preprocessing and statistical analysis as described above, 
114 clones and ESTs showed statistically significant signal values in both the 
experimental and control pools. Based on both raw signals and Log transformed values 
no sample showed a more than 2 fold up- or down-regulation. More specifically 58
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clones and ESTs were up-regulated in Smad4 transgenic samples (Figure 4.5) and 56 
were down regulated (Figure 4.6).
Clones were identified by NCBI’S UNIGENE database
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) for sequence similarity with 
known genes. Genes identified as significant in the array with known literature 
association to TGF-/3, apoptosis and/or p27Kipl were selected as candidates for further 
analysis. In total 7 genes were subjected to semi quantitative RT-PCR analysis: 
Adrenergic receptor beta 2 (ADRB2), Acid labile subunit of insulin like growth factor 
(ALS), Claudin 1 (CLDN1), Interferon-alpha inducible protein (Glp2), Nuclear Protein 1 
(NUPR1), Vitamin D Receptor (VDR) and Transducin beta like 3 (TBL3). 
Representative photos from RT-PCRs are illustrated in Figure 4.7. For primer sequences, 
PCR programs and product sizes see materials and methods (2.11).
91
Rank GI Number Name Log Ratio (exp/control) Fold Difference
Induced Genes
1 5244427 unknown 1.291642 1.65
2 5357450 Glp2: interferon, alpha-inducible protein 1.213956 1.68
3 4787196 unknown 1.1391243 1.75
4 50100 ADRB2: Adrenergic receptor, beta 2 1.1260933 1.58
5 2660687 lysosomal alpha-N-acetylglucosaminidase 1.1219273 1.71
6 6098665 Blvra: biliverdin reductase A 1.1193939 1.58
7 6008672 Mrpsl8a: mitochondrial ribosomal protein S18A 1.1136907 1.70
8 4832500 Ndufabl: NADH dehydrogenase (ubiquinone) 1 1.0986256 1.62
9 5488686 unknown 1.0950076 1.50
10 5477614 unknown 1.0921962 1.58
11 6099931 unknown 1.0870913 1.39
12 2765361 Acyl-CoA thioesterase 1.0838415 1.56
13 3426168 Ly86: lymphocyte antigen 86 1.0758751 1.37
14 5469733 Psmd5: proteasome 26S subunit, non-ATPase, 5 1.0746457 1.47
15 4441612 unknown 1.0741596 1.49
16 5497270 Fatty acid desaturase (61% identity) 1.072327 1.51
17 5103141 Mpdul: mannose-P-dolicho) utilization defect 1 1.0716086 1.43
18 1621612 Insulin-like growth factor binding protein 1.0704348 1.52
19 1213012 GOS2-like protein 1.0697198 1.42
20 6096137 unknown 1.0674593 1.39
21 6096364 Nola2: nucleolar protein family A, member 2 1.0664326 1.40
22 6008767 Vdr: vitamin D receptor 1.065815 1.38
23 2253712 Ras-related protein (DEXRAS1) 1.0639931 1.39
24 5490578 unknown 1.0605533 1.26
25 3127048 cGMP phosphodiesterase (PDE9A*1) 1.0591679 1.23
26 2892281 Fbxw5: F-box and WD-40 domain protein 5 1.058297 1.28
27 6096512 Mfap5: microfibrillar associated protein 5 1.0572589 1.33
28 6098645 Rtnl: reticulon 1(68.06% identity) 1.0572367 1.24
29 5474052 unknown 1.0526707 1.39
30 3860028 FK506 binding protein (Fkbp63) 1.0515857 1.31
31 200231 Hydroxymethylbilane synthase 1.0506994 1.25
32 5493772 Pip5k2c: phosphatidyIinositol-4-phosphate 5-kinase 1.0495584 1.25
33 6098472 Sec61b: Sec61 beta subunit 1.0486744 1.33
34 6291225 Entpd8: ectonucleoside 3P diphosphohydrolase 6 1.0453636 1.25
35 5931566 Cksl: CDC28 protein kinase 1 1.0447385 1.25
36 5469365 unknown 1.0432319 1.24
37 6097524 Vps4a: vacuolar protein sorting 4a 1.0432191 1.25
38 5492428 unkown 1.041302 1.20
39 1044898 RAD23b homolog 1.0401101 1.20
40 5496217 Pexllb: peroxisomal biogenesis factor l ib  (38.22%) 1.0382703 1.17
41 5771446 C7-1 protein 1.0379301 1.25
42 6253284 unknown 1.0378962 1.20
43 2592911 unknown 1.0361223 1.20
44 5910615 unknown 1.0350326 1.18
45 5498807 unknown 1.0341911 1.22
46 6098125 unknown 1.0319457 1.21
47 309180 Col5a2: procollagen, type V, alpha 2 1.0308961 1.20
48 6100432 unknown 1.0308267 1.21
49 5497337 unknown 1.0292498 1.14
50 1872796 unknown 1.0285726 1.19
51 6100870 Ormdl2: ORMl-like 2 1.0258752 1.14
52 55216 Valosin containing protein (S. cerevisiae) (83.01%) 1.0256666 1.17
53 6099582 unknown 1.0251573 1.15
54 5470060 unknown 1.0249225 1.15
55 2104688 alpha glucosidase II alpha subunit 1.0240113 1.13
56 5469805 Mitochondrial 28S ribosomal protein S21 1.0231315 1.14
57 6098503 unknown 1.0199849 1.11
58 6099715 unknown 1.0131259 1.06
Figure 4.5. List of significant up regulated gene transcripts in the BLG-Smad4 mice. 
Ranked is based on their log ratio. Raw Fold changes are also included. Percentages in 
brackets (wherever applicable) represents protein similarity to mouse.
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Rank GI Number Name Log Ratio (exp/control) Fold Difference
Repressed Genes
1 2911371 Igk-V22:Immun kappa light chain region 0.76857741 0.34
2 2232095 S107V1: mutated immunoglobulin heavy chain 0.85269757 0.45
3 4613476 Cldnl: claudin 1 0.85875699 0.70
4 3800794 unknown 0,86752001 0.63
5 984941 1115: interleukin 15 0,88006573 0.76
6 202451 Zinc finger protein 35 0,88523575 0.66
7 5311002 Psmb5: proteasome subunit, beta type 5 0,89122078 0.63
8 5492352 Btbdl: BTB (POZ) domain containing 1 0,89288354 0.69
9 6182775 unknown 0,90569688 0.67
10 473406 Hsp70-related NST-1 (hsr.l) 0,90759725 0.72
11 5476888 unknown 0,90885746 0.68
12 2991396 unknown 0,91045998 0.67
13 3417385 Mtap7: microtubule-associated protein 7 0,91929666 0.69
14 5496547 Nuprl: nuclear protein 1 0,91936337 0.58
15 2692014 Cdanl: (90% identity) 0,91959959 0.73
16 5905762 Nup50: nucleoporin 50 (99.57% identity) 0,92627494 0.71
17 1209719 B-cell leukemia/lymphoma 6 0,92941388 0.69
18 2979018 unknown 0,93016049 0.67
19 6097421 Spin: spindlin (99.56% identity) 0,93128578 0.73
20 5869933 Rab6ipl: Rab6 interacting protein 1 (98.36%) 0,93182718 0.72
21 6096384 unknown 0,93331829 0.96
22 6172102 unknown 0,9338621 0.78
23 2652035 unknown 0,93450206 0.76
24 4720470 Cggbpl: CGG triplet repeat binding protein 1 0,9391079 0.77
25 520479 loricrin gene 0,94417112 0.77
26 4602807 unknown 0,94511179 0.74
27 5498535 unknown 0,945216 0.83
28 5475706 unknown 0,94801975 0.81
29 192166 IgE-binding factor 0,94805197 0.76
30 5496643 unknown 0,94853873 0.80
31 1002423 yolk sac permease-like molecule 1 (YSPL-1) 0,94941527 0.87
32 897846 Ubiquitin-conjugating enzyme E2H 0,95087262 0.96
33 4320863 Tbl3: transducin (beta)-Iike 3 (25.62 identity) 0,9511102 0.79
34 191743 adipose fatty acid binding protein (422) 0,95123297 0.81
35 6098931 DllM oh35: DNA segment, Chr 11 (42.77%) 0,9512788 0.86
36 199142 Milk fat globuIe-EGF factor 8 protein 0,95698024 0.81
37 220404 Casein gamma 0,95706324 0.85
38 4615467 unknown 0,95732447 0.83
39 5184330 unknown 0,95769219 0.85
40 5469257 unknown 0,95980886 0.86
41 191574 Casein alpha 0,96008203 0.82
42 2642628 cysteine string protein mRNA 0,9603419 0.91
43 6514944 unknown 0,96144054 0.81
44 5491016 unknown 0,96147292 0.88
45 200991 Small nuclear ribonucleoprotein B 0,96314075 0.89
46 200949 Stearoyl-coenzyme A desaturase 1 0,96455125 0.86
47 194417 Mouse germline IgH chain gene 0,96525624 0.80
48 52848 mRNA for 21 kd polypeptide 0,96689535 0.86
49 988280 Y-box binding protein mYB-la mRNA 0,97026808 0.89
50 1938401 ribosomal protein L41 mRNA 0,97063618 0.86
51 5907730 Whsc2: Wolf-Hirschhorn syndrome 2(25.22%) 0,97252304 0.88
52 1199649 thymic shared antigen-1 (TSA-1) 0,97260459 0.86
53 1044896 RAD23a homolog (S. cerevisiae) 0,9750189 0.85
54 1360011 Artificial mRNA for single chain antibody scFv 0,97671671 0.88
55 5489762 unknown 0,97794677 0.95
56 5473355 Mapkl: mitogen activated protein kinase 1 (84.74%)0,98818655 0.99
Figure 4.6. List of significant down regulated gene transcripts in the BLG-Smad4 mice. 
Ranked is based on their log ratio. Raw Fold changes are also included. Percentages in 
brackets (wherever applicable) represents protein similarity to mouse.
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Figure 4.7. RT-PCRs for ADRB, ALS, CLDN1, GLP2, NUPR1, TBL3, VDR and HPRT 
as our control gene of choice. d3- day 3 involution. HPRT=Loading control.
Based on the RT-PCRs no major differences identified between Smad4 and wild type 
products except from the vitamin D receptor (VDR). VDR RT-PCR indicates an up- 
regulated gene expression profile in Smad4 compared to wild types, a result which is in 
agreement with the results obtained from microarray analysis.
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4.2.7 Smad4 over expression induces Vitamin D receptor.
Vitamin D receptor (VDR) is a receptor protein, member of the nuclear receptor super 
family (Carlberg 1995). VDRs are present in normal breast and many other epithelial 
tissues (Berger 1988). It has been demonstrated that VDR is dynamically regulated 
during pregnancy and lactation, but little is known about its specific functions. VDR is 
expressed at low levels in mammary glands of virgin rats and is up regulated in response 
to the differentiation inducing hormones cortisol, prolactin and insulin (Mezzetti 1987). 
Highest levels of VDR in mammary gland are seen during lactation, being maximal at 
day 3 involution (Colston 1988).
In order to confirm the mRNA up regulation observed in the RT-PCR I undertook a 
western blot analysis. This will also give the opportunity to identify whether a direct link 
between mRNA expression and protein levels come into agreement. Figure 4.8 illustrates 
a representative VDR western blot from day 3 involuting mice. There is an up-regulation 
of VDR's protein levels in the Smad4 transgenics compared to wild types at day 3 of 
involution.
VDR
Figure 4.8. Western blot analysis for vitamin D receptor protein. VDR is a 51kD protein. 
A clear up regulation of Vitamin D receptor at day 3 Smad4 mice compared to day 3 wild 
type. D3=Day 3 involution
d3 Smad4 d3 WT
4.2.8 Raw Data Analysis and the MBD2 case.
Methylation of CpG dinucleotides is an important epigenetic mechanism used by 
vertebrate cells to control transcription of many tissue specific genes (Bird 2002). To 
date, a direct link correlating DNA hypermethylation, hypoacetylation of histones, tightly 
packed chromatin, and transcriptional repression exists. CpGs in the genome are 
methylated as 5 methyl cytosine (approximately 85%) apart from large CpG islands in 
the promoters of genes which are unmethylated. The best example of this is the dense 
methylation of CpG promoters on the inactivated X chromosome and the Xist gene on the 
active X chromosome (Hendrich 2000). Effects of DNA methylation are mediated 
through proteins, which bind to symmetrically methylated CpGs. Such proteins contain a 
specific domain, the Methyl-CpG-Binding-Domain (MBD). Five MBD (MBD 1-4 and 
MeCP2) proteins have been identified to date all sharing the same functional Methyl 
Binding Domain (MBD domain) (Hendrich 1998).
It has been recently shown that, in colon cancer cell lines, MBD2 is associated with the 
aberrantly methylated promoters of silent p i4/pi 6 genes and this methylation-dependant 
association seems to be responsible for their silencing (Magdinier and Wolffe 2001). 
Furthermore, recently Sansom (2003) demonstrated that MBD2 deficient mice resisted 
intestinal cancer in terms of survival and number of adenomas caused by the tumour 
prone ApcMin/+ mouse. The various mechanisms leading to the methylation-dependant 
down regulation of transcription remain to be fully determined. However several lines of 
evidences indicate that, among them, the targeting of histone deacetylases (HDACs) 
complexes mediated by methyl-CpG binding proteins plays a major role (Bird and 
Wolffe 1999).
Abnormal methylation is a cause of human genetic diseases, including ICF 
(Immunodeficiency-Centromeric Instability-Facial anomalies syndrome) (Hansen 1999), 
and is involved in carcinogenic processes primarily through aberrant hypermethylation of 
tumor suppressor’s promoter regions (Jones 2002). MBDs are important constituent of
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the DNA methylation machinery, since they are directly involved in the mediation of the 
epigenetic signal (Bird 1999).
Raw data analysis indicated a down regulation of the MBD2 transcript (Figure 4.9). 
Therefore, it seemed appropriate to utilize conditional knockout MBD2 mice located in 
our animal house and try to investigate the consequences of MBD2 depletion in the 
mammary gland. My hypothesis was that the observed accelerated involution in the 
Smad4 transgenic mice can be correlated with the down regulation of MBD2.
Affymetrix Raw Expression for MBD2
Smad4
Figure 4.9. Raw expression values for MBD2 indicates a significant down regulation in 
the BLG-Smad4 transgenic mice compared to wild types at day 3 involution.
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4.2.8.1 Depletion of MBD2 from the mammary gland does not alter mammary 
gland architecture in virgin mice.
In order to investigate whether MBD2 depletion can create differences in mammary 
gland development, wholemounts were generated between MBD2/_ and wild type virgin 
mice. Figure 4.10 illustrates representative photos from 8 and 12 week old virgin mice.
12 weeks
Figure 4.10. Wholemount analysis ofMBD2"'and wild type virgin animals at 8 and 12 
weeks. No differences identified between the two genotypes in the development and 
overall architecture of the gland.
MBD2"'" MBD2 Wild Type
8 weeks
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4.2.8.2 Depletion of MBD2 from the mammary gland does not alter involution nor 
apoptosis of mammary epithelial cells at day 3 involution.
To investigate any possible alterations in the contribution of epithelial cells in mammary 
gland between MBD2 MBD2‘" and wild type animals a histological phenotypic 
analysis by sectioning and staining with hematoxylin-and-eosin (H&E) was undertaken. 
The number of mice for this analysis was at least 3 (n=3). Time point used was day 3 
involution. Quantification of slides as well as representative photos of the glands are 
illustrated in Figure 4.11.
MBD2-/- MBD2+/- MBD2+/+
Figure 4.11. Deletion of MBD2 does not alter mammary epithelial cell contribution in 
the mammary gland at day 3 involuting mice. A) Representative glands from MBD2' ', 
MBD2+‘ and MBD2 wild types. B) Quantification of slides for fat contribution showed 
no significant changes between the three genotypes. Scale bar 100pm.
A MBD2-/- MBD2+/- MBD2+/+
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To investigate any possible alterations in the regulation of apoptosis by depletion of 
MBD2, TUNEL analysis performed (Figure 4.12). In agreement with the above result 
MBD2 deletion from the mammary gland did not alter the apoptotic index.
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MBD2-/- MBD2+/- MBD2+/+
Figure 4.12. Deletion of MBD2 does not alter mammary epithelial cell apoptosis in the 
mammary gland at day 3 involuting mice. A) Representative glands from MBD2 
MBD2 ' and MBD2 wild types. Arrows indicate apoptotic cells. B) Quantification of 
slides for apoptotic cells showed no significant changes between the three genotypes. 
Scale bar 10pm.
MBD2+/- MBD2+/+
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4.3 Discussion.
4.3.1 Introduction.
The technique of expression profiling by means of hybridization to cDNA arrays offers a 
new tool for investigating the expression levels of thousands of genes simultaneously. I 
have utilized this technology for comparing gene expression profiles between conditional 
transgenic mice expressing human Smad4 in mouse mammary epithelial cells and wild 
type controls. Based on the results as written in Chapter 3 I decided to analyze mammary 
glands taken from day 3 involuting mice. My aim in this part of the project was to 
validate or identify genes differentially expressed in an over expressing Smad4 
environment.
4.3.2 Affymetrix Technology; Filtering, Data processing and Statistical Analysis.
Microarray results are influenced by various experimental errors (Dudoit 2002). 
Therefore, it was important to perform replicates of the experiments in order to assess the 
variability of gene expression levels in both Smad4 and wild type mice. For this purpose I 
decided to hybridize and compare 3 Affymetrix chips of Smad4 mice against 3 wild type 
ones.
Some basic data processing techniques and linear transformation of the data has been 
described in this chapter. In microarray analysis, exclusion of non-informative gene 
expression values (Absents) before normalize and statistically validate the data is of great 
importance. Currently, various filtering procedures exist and a comprehensive list of 
them can be found in Saviozzi (2003). The stringency of the filtering procedure can 
strongly affect (in a positive or a negative manner) the final results, as it can cause the 
loss of differentially expressed genes or increase the number of false positives 
contaminating the final results. For the purpose of this analysis I decided to filter the data 
by subtracting gene expression values which were considered as ‘Absents’ by the
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Affymetrix software. Filtering through the method described above reduced drastically 
the data from 12800 transcripts to 5808. This is a considerable reduction of ~65%, 
however, filtering of this kind is a necessity for removing false positives. By filtering out 
transcripts characterized as ‘Absents’ I reduce the possibility of identifying false 
positives but at the same time I exclude valuable targets that I wish to analyze.
A characteristic example is p27Kipl. Protein levels of p27Kip] were found to be 
significantly increased at day 3 involuting BLG-Smad4 transgenic mice compared to 
controls (Chapter 3). Unfortunately, p27KipJ transcript was identified as ‘Absent’ in all 6 
Affymetrix chips, and therefore was filtered out from further analysis despite my interest 
in analyzing mRNA levels of this molecule. From the observed absence of p27KipI mRNA 
expression at day 3 involution I can hypothesize that its RNA expression probably occurs 
at an earlier time point (day 1 or 2 of involution) and regulate p27Kipl,s protein over 
expression as observed in the day 2 and day 3 involution western blot samples.
Array experimental conditions can strongly affect microarray hybridization intensities. It 
has been demonstrated that sources of error are multiplicative and can strongly affect true 
expression levels (Hartemink 2001), especially if genes are moderately expressed (Rocke 
2001). Therefore, normalization of gene expression data is a crucial preprocessing 
procedure essential for nearly all gene expression studies in which data from one array 
(or set) is compared to data from another array (or set). A number of normalization 
approaches may be taken into account (Kim 2000, Colub 1999), each of which utilize 
different software and algorithms, however, a gold standard method for microarray data 
normalization has not been defined. For a representative review on different 
normalization methods see Wolkenhauer (2002).
For the purpose of this data normalization I utilized a method of data transformation 
which is suggested by Affymetrix; log transformation. Log transformation serves data in 
a dual role. Firstly, it accomplishes reduction of signal errors (in an absolute sense) and 
furthermore, it transforms data in a normal like shape. Transformation of the data to a
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linear form allows statisticians to perform parametric statistical tests. Data transformation 
has been achieved by logging in the base of 2.
I have utilized a publicly available software SAM (Significant Analysis of Microarrays) 
(Tusher 2001) which can be located at http://www-stat- 
class.stanford.edu/SAM/SAMServlet for identifying differentially expressed genes. SAM 
is a software specifically designed for normalizing (by logging) and analyzing microarray 
data. Analysis is performed in logged microarray values by assimilating a set of gene- 
specific t tests. Genes with scores over a specified by the user cut off value are 
considered as significant. SAM has also the ability to identify false differentially 
expressed genes (genes which have been identified by chance) amongst the significant 
pool (False Discovery Rate) by analysing permutations of the measurements.
SAM was unable to identify differentially expressed genes due to the fact that the 
observed significant targets were lower than the expected ones. This was demonstrated 
when statistical analysis was undertaken manually by a student’s t-test. In this test the 
significant differentially expressed genes identified were 114 (observed) when the 
expected False Discovery Rate (FDR) out of 5800 transcripts in a 5% probability risk 
level is 290 (see below).
Following data transformation by logging, I performed a parametric t-test. Parametric 
statistics test the hypothesis that one or more treatments (in our case BLG-Smad4) have 
no effect on the mean (or median) of a chosen variable. 114 ESTs and clones were 
identified as statistically significant in a 5% probability risk level. Statistically significant 
targets show identical expression values between experimental and control groups and 
exclude the possibility of data “contamination” by outliers generated by experimental 
noise.
The number of statistically significant identified targets is “relatively few” compared to 
the thousands analyzed. This failure to identify many changes may reflect the dynamics 
and composition of the mammary gland itself. As stated at chapter 1 the mammary gland
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is a very dynamic tissue. Epithelial cells undergo programmed cell death and are 
substituted by adipocytes during involution. The quantity of epithelial cells as well as 
their quality regarding RNA integrity and expression stage cannot be precisely controlled 
in this in vivo approach. The above factors may well combine in contributing to the 
generation of biological outliers between samples i.e. samples with different expression 
values for a gene in the same pool, and therefore reduce the number of statistically 
significant targets. To overcome this potential problem I attempted to pursue microarray 
analysis by performing primary mammary cell cultures where cell quantity, quality and 
RNA expression status can be controlled. As I illustrate in Chapter 5 this is the method of 
choice for extracting RNA and is a method of producing more statistically significant 
results than a pure in vivo approach.
4.3.3 Smad4’s Expression profile.
No major up- or down- regulated genes were identified following calculation of the ratios 
of the mean logs between experimental and control groups. Ratio of the log mean values 
above 1 were considered as 2 fold up-regulated in the BLG-Smad4 mice compared to 
experimentals whereas ratios below 1 to 0 considered as down regulated (Note: Log2 2=1, 
Log2 0.5=-1). All statistically significant targets showed ratios between 1.29 to 0.76. 
More specifically 58 clones and ESTs were induced in Smad4 transgenic samples and 56 
were repressed.
The observed ratio of log means indicate close mRNA expression profiles at day 3 
involution between experimental and control groups despite the phenotypic and 
molecular changes as observed and written in chapter 3. Possible explanations for this 
phenomenon might be the time point itself or that these sets of data need more replicates. 
I hypothesize that at day 3 of involution large numbers of epithelial cells have already 
commit apoptosis therefore mRNA signal for the genes responsible for this programmed 
cell death probably may have occurred at earlier time points (e.g. the p27Kipl case). 
Therefore, it may be interesting to repeat the same experiments during day 2 or even day
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demonstrated in transient experiments a synergistic activation of the osteocalcin gene 
promoter by binding of a Smad3-Smad4 heterodimer and Vitamin D receptor in their 
cognate DNA recognition elements (SBE and Vitamin D Receptor Element-VDRE 
respectively) located in close proximity between them (Subramaniam 2001). Smad3 acts 
as a co-activator of Vitamin D receptor and positively regulates the VDR signaling 
pathway. Negative regulation of VDR function has also been demonstrated both in vivo 
and in vitro by Smad7 inhibition in the formation of the VDR-Smad3 complex, whereas 
Smad6 had no effect (Yanagi 1999).
Following all data handling and RT-PCR analysis I identified up regulation of the 
Vitamin D receptor mRNA level. Western blot analysis also indicated an up-regulation of 
VDR protein levels in the Smad4 transgenics compared to wild types at the 3rd day of 
involution. This result agrees with previous findings correlating increased levels of TGF- 
/3 with VDR induction. What remains to be elucidated is whether VDR’s induction is due 
to increased levels of Smad3 brought to the nucleus by Smad4 or by Smad4 alone.
4.3.5 MBD2.
Affymetrix raw data indicated a down regulation of MBD2 mRNA levels in day 3 
involuting Smad4 transgenic mice. MBD2 belongs to the family of the methylation 
binding proteins which responsible for the methylation of CpG dinucleotides. DNA has 
been characterized as an important epigenetic mechanism for controlling transcription of 
many tissue specific genes (Bird 2002). It has been demonstrated that promoter 
methylation by MBD2 causes gene silencing and colon cancer (Magdinier and Wolffe 
2001). In contrast Sansom (2003) showed that MBD2 depletion suppressed and resistance 
in intestinal cancer in terms of survival and number of adenomas caused by the tumour 
prone ApcMin/+mouse. Taking this into account it seemed appropriate to hypothesize that 
MBD2 repression in the Smad4 over expressing mice could be one of the reasons for the 
accelerated involution and the increased apoptotic index and that MBD2 could regulate 
mammary gland development or involution.
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In order to investigate the above hypothesis I decided to undertake a wholemount 
analysis of virgin knockout MBD2 mice as well as analysis at day 3 of involution. 
Wholemount analysis in the MBD2 knockout mice could provide valuable information 
regarding its role in mammary gland development while investigation of the same mice at 
day 3 of involution could shed light in the role of MBD2 in mammary epithelial cell 
apoptosis. Both analyses indicated that MBD2'7' and MBD2+/‘ did not have an altered 
phenotype or apoptotic differences when compared to wild type glands.
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Chapter 5-Sm ad-Stat Interactions and M icroarray A nalysis o f  Stat3+/\
5.1 Introduction.
5.1.1 STATs and the mammary gland.
Signal Transducers and Activators of Transcription (STATs) proteins comprise a family 
of transcription factors latent in the cytoplasm that participate in normal cellular events, 
such as differentiation, proliferation, cell survival, apoptosis and angiogenesis. STATs 
get activated in response to many cytokines and growth factors (Schindler 1995) and 
have been shown to be capable of both activating and suppressing gene transcription 
(Fukada 1998) as well as act as growth suppressors (Kaplan 1998) or growth promoters 
(Catlett-Falcone 1999) depending on the particular ST AT and the promoter sequence to 
which they bind.
The STAT signaling pathway has well been defined as an archetypal membrane to 
nucleus signal transduction pathway, which utilizes the Janus kinase (JAK) proteins to 
achieve a cascade of phosphorylation signals leading to regulation of gene transcription. 
The classic activation pathway involves the cytokine ligand Interferon-y (IFNy) which 
upon binding to its corresponding IFNy- receptor induces the oligomerisation of its 
subunits, leading to phosphorylation and activation of the pre-associated JAKs. The 
phosphorylated JAKs in turn phosphorylate the IFNy receptor, allowing STATs to bind, 
get phosphorylated and form a homodimer that migrates to the nucleus (Figure 5.1). The 
specificity of STATs for receptors appears to depend on the cell type and a single ligand 
can activate a number of different STATs. To date seven STAT proteins have been 
identified and divided into two functional groups. STAT2, 4 and 6 comprise the first 
group due to their activation by a small number of cytokines and their role in the 
development of T-cells. STAT 1, 3 and 5 (Stat5a and Stat5b), comprise the second group 
due to their activation by a series of ligands and their involvement in the development of
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mammary gland and embryogenesis. This later group of STATs plays an important role 
in controlling cell-cycle progression and apoptosis (Bromberg 2002). It has been 
demonstrated that STATs regulate transcription of a number of genes including: IRF-1, 
Bcl-XL, cyclin D l, PIM-1, c-Myc and p21.
5.1.2 Role of STAT3 in Mammary Gland Development.
Analysis of phosphorylated protein levels and DNA binding activities have shown that 
STAT3 is activated at day 5 of pregnancy (Philip 1996). Furthermore, initiation of 
involution is characterized by changes in the phosphorylation/activity of STAT3 and 
STAT5a (Liu X 1996). STAT5a and STAT3 have reciprocal patterns of phosphorylation 
with decreasing STAT5a levels and increasing STAT3 at the begging of involution (Li 
1997). In the mammary gland, STAT5 activation can be induced by Prolactin (PRL), 
Epidermal Growth Factor (EGF) and Growth Hormone (GH) (Gallego 2001), whereas 
factors that activate STAT3 during involution are unknown.
Conditional STAT3 knockout mice have demonstrated that in the absence of STAT3, 
involution is not initiated for at least 3 days following the removal of pups and that extent 
of apoptosis in mammary epithelial cells is significantly reduced. Mammary glands in the 
conditional knockout animals do eventually undergo remodeling, demonstrating that a 
compensatory mechanism exist. However, remodeling is not complete and alveolar 
structures remain, indicating that a disruption of the remodeling pathways involving 
STAT3 leads to the survival of cells otherwise destined to undergo apoptosis (Chapman 
1999).
Molecularly, STAT3 knockout animals have demonstrated possible mechanisms 
responsible for initiating delayed involution and apoptosis by up regulating p21 and p53 
levels as well as levels of STAT1, a dimerization partner for STAT3. No changes 
occurred in the Bcl-xl gene while levels of IGFBP-5 (Insulin Growth Factor Binding
j
protein-5) that normally increase at the 2 day of involution, remained unchanged.
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Figure 5.1. STAT signaling pathway. The classic activation pathway involves the 
cytokine ligand INFy receptor subunits, leading to phosphorylation and activation of the 
preassociated JAKs, which in turn phosphorylate the IFNy receptor allowing STAT1 to 
dock. STAT1 is then phosphorylated and forms a homodimer that migrates to the nucleus 
where regulates transcription.
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5.1.3 STAT-SMAD interaction.
TGF-P and Smads have been shown to be inhibited by the IFNy/STAT pathway (Ulloa 
1999). In the same paper it has been demonstrated that IFNy inhibits the TGF-p induced 
phosphorylation of Smad3 and its attendant events, namely the association of Smad3 with 
Smad4, the accumulation of the complex in the nucleus, and the activation of TGF-p- 
responsive genes. Furthermore, through JAK1 and STAT1, IFNy induces the expression 
of Smad7, an I-Smad which prevents the interaction of Smad3 with the TGF-p receptor. 
These observations were the first to indicate a possible mechanism of transmodulation 
between the STAT and Smad signal-transduction pathways.
Transcriptional activation by R-Smads has been shown to occur, in part at least, by their 
ability to recruit the general coactivators p300 and CBP (Feng 1998, Shen 1998). p300 
and CBP have histone acetyl transferase (HAT) activity, suggesting that their recruitment 
by a Smad complex may increase transcription of target genes by altering nucleosome 
structure and thereby remodeling the chromatin template. This interaction is directly 
mediated by the MH2 domain of R-Smads. p300 and CBP are large proteins with 
separate regions for interaction with different transcription factors. It has been suggested 
that the cooperative signaling of BMP2 and the cytokine LIF (Leukemia Inhibitory 
Factor) in astrocyte formation is mediated by a Smadl-Stat3 complex bridged by contacts 
with separate regions of p300 (Nakashima 1999). In addition, recently it was reported 
that PIAS3, a member of the protein inhibitor of activated STAT (PIAS) family interacts 
with Smad proteins, most strongly with Smad3. This interaction is accomplished via 
Smad3’s MH2 domain both in vivo and in vitro through p300/CBP and leads to Smad 
induced transcriptional activity (Long 2004). Figure 5.2 illustrates a representative 
diagram of the Smad-STAT interplay.
I l l
Smad-Stat3 Interaction
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LIF (Leukemia Binding Factor)
Smad 1/5
Smad 1/5
Smad 1/5
SMAD4
Figure 5.2. Cooperativity between Smad and Stat signaling pathways via p300/CBP.
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5.1.4 STAT3 Knockout.
In order to dissect the functions of individual components of complex biological systems 
it has become almost routine to engineer some type of transgenic mouse. This approach 
can yield immense amounts of information regarding the functions of the molecule in 
question and can also answer questions pertaining to redundancy and compensation. This 
approach is often the only option to fully understand the role that a particular molecule 
plays in an in vivo context and, combined with the other analyses that will be applied (see 
below), it is an approach that seems entirely appropriate for this project
For the purpose of this chapter I utilized a conditional Stat3 knockout mouse. Due to 
embryonic lethality of the STAT3 knockout mouse (Takeda 1997), a conditional 
knockout was been generated (Akaishi 1998) by utilizing the Cre-lox recombination 
system. A floxed Stat3 strain, in which an exon responsible for tyrosine phosphorylation
FI/has been flanked by loxp sites and crossed to a null Stat3 animal to generate a Stat3 '. 
This animal was further crossed to an animal carrying a BLG-Cre transgene. In this way 
Cre recombinase is directed specifically to mammary epithelial cells during pregnancy 
and lactation and causes recombination and subsequent deletion of STAT3’s loxp site.
5.1.5 Aims.
This chapter is divided into two parts. The first part will address the interacting Smad4- 
Stat3 role in the mammary gland by crossing the BLG-Smad4 transgenic construct onto a 
mammary conditional Stat3 ‘floxed’ background carrying a BLG-Cre construct. Deletion 
of Stat3 from the mammary gland delayed involution (Chapman 1999), while Smad4 
over expression in the mammary gland results in accelerated involution with a subsequent 
Stat3 down regulation at day 3 involution (Chapter 3). Here a comparison of BLG- 
Smad4-BLG-Cre-Stat3Fzy~ against BLG-Cre-Stat3Fzy~ mice will be investigated at day 3 of 
involution.
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The second part of this chapter will investigate the consequences of a conditional deletion 
of Stat3 in the mammary gland by undertaking a microarray approach. In this way I 
aimed to identify alterations in the expression profile of known STAT3 targets and 
indicate new ones. For this attempt a comparison of mammary gene expressions between 
Stat3+/' and Stat3+/+ mice will be carried out. In contrast to the Smad4 microarray 
experiments (see chapter 4), it was decided to approach this question by utilizing RNA 
from primary mammary epithelial cell cultures. Primary mammary cell cultures were 
used in order to avoid problems created by adipose tissue contamination.
5.2 Results
5.2.1 Analysis of Over Expressing Smad4 in a Stat3 Null Environment.
5.2.1.1 Smad4 over expression does not influence involution in a conditional Stat3 
knockout mouse.
To investigate any possible alterations in the contribution of epithelial cells in the
P I  /mammary gland between BLG-Smad4-BLG-Cre- Stat3 ' (experimentals) and BLG-Cre- 
Stat3FZ/' (controls) a histological phenotypic analysis by sectioning and staining with 
hematoxylin-and-eosin (H&E) was undertaken. The number of mice for this analysis was 
at least 3 (n=3). Following the observation of decreased STAT3 expression at day 3 of 
involution in the BLG-Smad4 mice I generated sections from the same time point. As in 
Chapter 3, mice were allowed to lactate for 10 days (6-8 pups) and then pups were 
withdrawn to initiate involution. Figure 5.3A illustrates representative glands from both 
experimental and control mice. Both genotypes exhibited a similar phenotype. Alveoli 
remained intact and distended and although a small number of apoptotic cells seen, 
glands retained the general appearance of a lactating gland. To quantify the amount of
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involution occurred the areas of the glands occupied by adipocytes were measured and 
illustrated in Figure 5.3B.
Blg-Smad4-Blg-Cre S t a t 3 ^  Blg-Cre S ta t3 "y‘
lOO^im
Blg-Smad4-Blg-Cre Blg-Cre Stat3 Fi/-
Stat3FI/-
Figure 5.3. Smad4 over expression does not influence involution in a conditional Stat3 
knockout mouse at day 3 of involution. A) Representative H&E sections from BLG- 
Smad4-BLG-Cre- Stat3My' and Blg-Cre Stat3fI/'. Microscope scale x40. B) BLG-Smad4- 
BLG-Cre Stat3F7y‘ (open bar), BLG-Cre StatS^' (solid bar). Each bar represents the mean 
of data collected from at least 3 mice (n=3). Error bars represent standard error of the 
mean. p<0.05 Mann-Whitney U test. Scale bar 100pm.
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5.2.1.2 O ver expression of Sm ad4 does not a lter apoptosis in a conditional Stat3 
knockout mouse.
In order to confirm the above result it seemed appropriate to examined levels of apoptosis 
in the mammary tissues of both genotypes by performing TUNEL analysis. Figure 5 .4 A 
illustrates two representative glands from BLG-Smad4-BLG-Cre Stat3f7y and BLG-Cre- 
Stat3/Z/' mice respectively (Figure 5.4A). Percentages of TUNEL positive cells were 
determined for both genotypes at day of 3 involution and are presenting in the graph 
below (Figure 5.4 B).
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Figure 5.4. Similar levels of apoptosis between BLG-Smad4-BLG-Cre-Stat3FL7' (open 
bar) and BLG-Cre-Stat3FI7' (solid bar) at day 3 involution. Each bar represents the mean 
data collected by at least 3 mice. Error bars represent standard error of the mean. p<0.05 
Mann-Whitney U test. Scale bar 10pm.
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Taken together the above data I conclude that the BLG-Smad4 transgene does not modify 
the STAT3 phenotype at day 3 of involution.
5.2.2 Stat3 M icroarrays.
5.2.2.1 P rim ary  M am m ary Epithelial cell cultures.
Stat34' and Stat3+/+ mice (Takeda 1997) were mated in order to derive pregnant females, 
which were then sacrificed at their 16-18 day of pregnancy. Primary mammary epithelial 
cell cultures utilizing all mouse mammary glands were then undertaken (Figure 5.5).
Figure 5.5. Representative photos illustrating primary mammary cell cultures from a 
STAT3+/\  A) x60 B) xlO magnification.
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5.2.2.2 The Stat3_/‘ deficient cultures were not viable.
The original objective were to investigate the consequences of Stat3 depletion in the 
mammary gland via a scaled approach in which Affymetrix chip arrays could identify 
changes in mRNA levels from Stat3_/' and Stat3+/' compared to wild type Stat3 (Stat3+/+). 
Both wild and type and heterozygous Stat3 mammary epithelial cell cultures had a 
lifespan of 6-7 days before commit apoptosis. I found that sufficient RNA for performing 
chip hybridization without RNA amplification was available after 5 days of culturing in 
35mm Petri dishes. Although RNA was extracted successfully from Stat3+/'and Stat3+/+at 
this time point, Stat3"7' epithelial cells exhibited a failure to reach adequate cell quantities 
before committing apoptosis (no picture has been taken). Therefore, I was unable to 
extract adequate amounts of RNA and perform chip hybridization. RNA amplification for 
Stat3'A samples was not undertaken due mainly to lack of adequate time before 
completing this PhD.
5.2.2.3 Affymetrix chips and Data Processing.
Following in vitro RNA extraction and RNA processing as described in 2.7, labeled 
fragmented oligonucleotides hybridized to 6 U74v2 Affymetrix chips (3 experimentals: 
Stat3‘/+ and 3 controls: Stat3+/+) and analyzed with Affymetrix Gene Chip Hybridization 
and Analysis system (University of Wales College of Medicine).
Chip consistency of errors was investigated through summation of Affymetrix’s control 
gene raw data as described in Chapter 4.2.2. Figure 5.6 illustrates the comparison of 
control gene errors between the 6 Affymetrix chips. From this graph I can conclude that 
all experimental and wild type chips show similar levels of error signal intensities 
amongst them. Similarity of control error intensities indicate similar patterns of 
hybridization procedures for each chip, thereafter indicate that all of our chips can be 
used further for gene expression analysis without creating noise in the data.
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Filtering out “Absent” calls performed as described in 4.2.3. Filtering reduced the data 
from 12808 to 5312 transcripts. As in 4.2.4 data normalized by logging raw values in the 
base of 2. A two tail Student t-test identified 98 transcripts as significant potential targets 
at a 1% risk level. Comparison of Stat3+/' mice to wild type Stat3 indicated 46 targets 
with a significantly induced expression (Figure 5.7) and 52 with significantly reduced 
expression (Figure 5.8). Contrary to the Smad4 microarray experiments the FDR is 
almost half (53 targets) than the significant altered identified targets indicating that 
extraction of RNA from primary mammary gland tissues can produced better quality of 
results probably due to the avoidance of adipose contamination.
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Figure 5.6. Summation of signal intensities from control genes. Each bar represents a 
different chip. Experimental (Exp) and wild type (WT) chips have a similar level of error 
signal intensities between group chips as well as between groups.
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Rank GI Number Name Log Ratio (exp/control) Fold Difference
Induced Genes
1 5125856 Cav: caveolin, caveolae protein 1,173589 2,19
2 192705 Crabp2: cellular retinoic acid binding protein II 1,171748 1,72
3 1907082 . hexokinase 2 1,143682 1,92
4 5777875 ubiquitin specific protease 49 1,125872 1,59
5 5489704 Pla2gl2a: phosphoiipase A2, group XIIA 1,12541 1,90
6 6099674 Plekhb2: pleckstrinB (evectins) member 2 (40.87%) 1,105862 1,78
7 722340 F gfrl: fibroblast growth factor receptor 1 1,104163 1,67
8 1027499 Zfhxla: zinc finger homeobox la 1,102586 1,36
9 6390211 unknown 1,088566 1,41
10 2605641 Rgsl6: regulator of G-protein signaling 16 1,087794 1,55
11 577633 Bmprla: bone morphogenetic rec type 1A (94.66%) 1,085905 1,40
12 4103990 Spata6: spermatogenesis associated 6 1,083911 1,46
13 4586867 G gpsl: geranylgcranyl diphosphate synthase 1 1,08346 1,36
14 2516393 unknown 1,075543 1,38
15 3171941 Diap2: diaphanous homolog 2 (56.58%) 1,074847 1,25
16 454834 peroxisome membrane protein (PMP70) 1,066383 1,39
17 193563 G gta l: glycoprot galactosyitransferase alpha (96.80)1,064984 1.34
18 436576 Cpox: coproporphyrinogen oxidase 1,064174 1,32
19 5907418 unknown 1,05737 1,23
20 3493348 AmpU3 1,050648 1,19
21 46195799 Rgl2: ral guanine nucleotide 
dissociation stimulator,-like 2
1,046892 1,21
22 3750037 unknown 1,046159 1,26
23 4218069 TbpU: TATA box binding protein-like 1 1,045515 1,15
24 5490939 unknown 1,042793 1,14
25 2062606 Kif5b: kinesin family member 5B 1,04007 1,22
26 5473499 unknown 1,038824 1,25
27 3372490 Tulp3: tubby-like protein 3 1,038494 1,22
28 1151214 Lamb3: Iaminin, beta 3 1,03667 1,20
29 198776 L d h l: lactate dehydrogenase 1, A chain (95.73%) 1,03454 1,30
30 2959869 Syngr2: synaptogyrin 2 1,033133 1,19
31 4602583 unknown 1,032163 1,18
32 5477102 Atp6v0b: ATPase, H+ transporting, V0 subunit B 1,031113 1,21
33 2952521 Golga4: goigi autoantigen golgin subtype a4 1,030251 1,16
34 5488570 RB4 INHUMAN Ras-related prot Rab4B(85.23%) 1,029713 1,15
35 5493810 unknown 1,029672 1,15
36 3805948 5T4 oncofetal trophoblast glycoprotein gene 1,027733 1,13
37 5469572 Ssr3: signal sequence receptor, gamma 1,026454 1,19
38 5475602 phosphopyruvate hydratase (94.06%) 1,025939 1,21
39 6095958 unknown 1,025113 1,14
40 5488417 unknown 1,024496 1,13
41 1771285 H dacl: histone deacetylase 1 1,024239 1,13
42 1405932 Pkm2: pyruvate kinase M2 isozyme 1,022168 1,19
43 6467220 type I peroxiredoxin 1,021917 1,18
44 5931552 Morf412: mortality factor 4 like 2 (73.66%) 1,021106 1,15
45 50986 Itgbl: integrin beta 1 (fibronectin receptor beta) 1,011812 1,09
46 2645736 Ubl 1: ubiquitin-homoiogy domain protein 1,0067 1,04
Figure. 5.7. List of significant up regulated gene transcripts in the Stat3+/* mice. Ranked 
is based on the log ratio (Stat3+/'/wild types). Raw Fold changes are also included. 
Percentages in brackets (wherever applicable) represents protein similarity to mouse.
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Rank GI Number Name Log Ratio (exp/control) Fold
Repressed Genes
1 3108056 Cipp: channel-interacting PDZ domain protein 0,784376 0,50
2 6375851 unknown 0,812498 0,54
3 2074486 Ncoa6: nuclear receptor coactivator 6 0,83668 0,59
4 3411010 Pparbp: peroxisome proliferator activated 0,872563 0,53
5 4729959
receptor binding protein
Uxsl: UDP-glucuronate decarboxylase 1 (26.84%) 0,897974 0,77
6 2857305 unknown 0,904367 0,67
7 4616082 heterogeneous nuclear ribonudeoprotein HI (62.12%) 0,912549 0,67
8 5469973 unknown 0,915006 0,73
9 6096519 S12207 hypothetical protein (68.57%) 0,916512 0,68
10 4663775 unknown 0,918826 0,74
11 533330 Top2b: topoisomerase (DNA) II beta 0,920983 0,70
12 5477783 unknown 0,923339 0,67
13 2125862 Sfrs3: splicing factor, arginine/serine-rich 3 (SRp20) 0,926954 0,68
14 2893204 unknown 0,927234 0,73
15 2687851 Z h xl: zinc fingers and homeoboxes protein 1(99.54%) 0,929368 0,76
16
17
1903415
404930
Eif4g2: eukaryotic translation initiation factor4,
gamma 2
Sntal: syntrophin, acidic 1
0,929711
0,930577
0,73
0,68
18 3733840 Hnrpal: heterogeneous nuclear 0,934669 0,76
19 5470226
ribonucleoprotein A1 (79.09%)
Fcm la: feminization 1 homolog a (36.40%) 0,940826 0,77
20 5871950 unknown 0,941204 0,78
21 1871224 Rbll: retinoblastoma-like 1 (p i07) 0,941338 0,78
22 5496771 unknown 0,941762 0,78
23 5497628 unknown 0,941794 0,75
24 1098540 Osp94: osmotic stress protein (61.97%) 0,941949 0,76
25 2755261 unknown 0,942182 0,74
26 6099890 unknown 0,945984 0,77
27 54158 Spl gene (31 end) 0,946736 0,77
28 1545956 Ebp: phcnylalkylamine Ca2+ antagonist 0,951864 0,79
29 6095959
(emopamil) binding protein 
unknown 0,952589 0,82
30 4092839 Ptprj: protein tyrosine phosphatase, receptor type, J 0,953031 0,83
31 6340759 unknown 0,958507 0,79
32 191603 Chrnbl: cholinergic receptor, nicotinic, 0,959579 0,79
33 5907081
beta polypeptide 1 (99.80%) 
unknown 0,959798 0,84
34 5476816 unknown 0,960562 0,81
35 6100589 EGL nine homolog 2 0,960622 0,79
36 1546828 Idh3g: isocitrate dehydrogenase 3 (NAD+), gamma 0,961855 0,80
37 6100992 unknown 0,963955 0,82
38 199762 M odi: malic enzyme 0,964275 0,81
39 6096493 unknown 0,965816 0,85
40 4249732 low density lipoprotein B 0,966350 0,84
41 6097084 unknown 0,969016 0,83
42 5492751 unknown 0,969466 0,85
43 4262394 Cldn3: claudin 3 0,971961 0,81
44 2506077 H iatl: hippocampus abundant gene transcript 1 0,974607 0,88
45
46
1550786
471977
Dgcr2: DiGeorge syndrome critical region gene 2
(99.64%)
Ppplcb: protein phosphatase 1, catalytic subunit,
0,976625
0,976997
0,89
0,86
47 2719590
beta isoform (99.69%) 
unknown 0,977711 0,86
48 5471741 Jakl: Janus kinase 1 0,979612 0,88
49 5492041 Trpc4np: transient receptor potential cation channel, 0,982929 0,90
50 5489559
subfamily C, member 4 associated protein 
unknown 0,983669 0,93
51 5476173 Snx6: sorting nexin 6 (66.67%) 0,986389 0,91
52 6098087 unknown 0,988999 0,93
Figure 5.8. List of significant down regulated gene transcripts in the Stat3+/‘ mice. 
Ranked is based on the log ratio (Stat3+/7wild type) Raw Fold changes are also included. 
Percentages in brackets (wherever applicable) represents protein similarity to mouse.
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5.2.2.4 Data Clustering.
Another way of visualizing alterations in gene expression profiles is via data clustering. 
The basic concept in clustering is to identify and group co-regulated and functionally 
related genes together and then try to correlate the observations to biology. There are 
several methods of clustering like Hierarchical clustering (Eisen 1998), K-means 
(Tavazoie 1999) and self organizing maps (SOMs) (Tamayo 1999). For the purpose of 
this analysis I have chosen to cluster my data in a Hierarchical mode.
Hierarchical clustering is a statistical method for identifying relatively homogeneous 
clusters. The hierarchical clustering algorithm either iteratively joins the two closest 
clusters starting from single clusters (bottom up approach) or iteratively partitions 
clusters starting from the complete set (top down approach). After each step, a new 
distance matrix between the newly formed clusters and the other clusters is recalculated. 
The complete linkage, average linkage and single linkage methods use maximum, 
average and minimum distances between the members of the two clusters respectively.
Average Hierarchical data clustering performed between 3 Stat3+/' and 3 wild type Stat3 
samples. In average linkage, the distance between two clusters is considered to be equal 
to the average distance from any member of one cluster to any member of the other 
cluster. The hierarchical clustering can be represented as a tree, or a dendogram. Branch 
lengths represent the degree of similarity between the genes. Average linkage analysis at 
a 1% cut off produced the histogram illustrated in Figure 5.9.
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Figure 5.9. Hierarchical clustering o f  gene expression matrices. The image shows an 
average linkage clustering o f 99 genes constructed between Stat3+/" (352, 188, 198) and 
Stat3 wild types (162, 164, 237). The color image on the left shows the numerical values 
encoded by color according to the method introduced by the EASI software. Red is used 
to represent up-regulated values and green down-regulated.
123
5.3 Discussion.
5.3.1 Introduction.
In this part of the thesis I have utilized conditional Stat3 knockout mice for investigating 
a) the consequences of an over expression of Smad4 in a Stat3 null environment in the 
mammary gland and b) the alteration of mRNA levels of various targets in primary 
cultured mammary epithelial Stat3+/' cells compared to Stat3 wild types by performing 
microarray analysis.
ST AT proteins comprise a family of transcription factors important for regulating a vast 
array of cellular events including apoptosis (Bromberg 2002). It has been demonstrated 
that STAT3 plays an important role in promoting apoptosis during mammary gland 
involution by up regulating p21 and p53 levels.
5.3.2 Smad-Stat Interactions.
The decision to over express Smad4 in a STAT3 null mammary gland environment was 
based on the fact that western blot analysis in Smad4 transgenic mice showed a decrease 
in STAT3 levels at the 3rd day of involution accompanied by an acceleration of mammary 
epithelial cell death. By contrast, mammary gland STAT3 knockout animals have 
demonstrated delayed involution and decreased levels of apoptosis (Chapman 1999). The 
investigation I undertook was based on the hypothesis that over expression of Smad4 in a 
STAT3 null environment could restore STAT3’s delayed involution.
Following quantification of H&E slides between Blg-Cre-Smad4-Blg-Cre-Stat3^" and 
Blg-Cre- Stat3^' at day 3 involution, no differences were observed in their mammary 
epithelial cell contribution. TUNEL investigation for the apoptotic index of these mice at 
the same day agreed with the above result and showed no significant differences.
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Although, cooperation between Smads and STATs has been demonstrated in a number of 
occasions (Ulloa 1999, Nakashima 1999) and over expression of Smad4 decreased 
STAT3 levels at day 3 involuting mice, Smad4 over expression in STAT3 null mammary 
glands did not restore STAT3’s phenotype. Further experimentation is necessary for 
identifying relative levels of various cellular co-activators and transcription factors that 
may govern this net effect.
5.3.3 Microarray Analysis of Stat3+/“ Primary Mammary Cell Cultures.
In this part of the project I decided to undertake a microarray analysis by utilizing 
mammary STAT3 knockout animals. My aim was to investigate mRNA alterations of 
various molecules by comparing Stat3'7' and Stat3+/'to wild type mammary glands.
In order to overcome problems such as fat contamination, mammary glands were 
subjected to primary cell culture. Although adequate amounts of RNA were possible to 
extracted from both Stat3+/" and Stat3 wild types that was not the case for Stat3"/\  
Mammary epithelial cells of this genotype demonstrated inability to create clusters and 
remain viable for more than 2-3 days. Inability of Stat3_/' cells to reach adequate 
confluency in this time resulted in extraction of low amounts of RNA which was 
insufficient for performing in vitro transcription and labeling for Affymetrix 
hybridization. The option of performing RNA amplification was abandoned for fear that 
amplification may create differences in the overall experiment when compared to un­
amplified samples as well as due to time constrains for the completion of this thesis.
Following data filtering, normalization and statistical analysis 98 transcripts were 
identified as significant at a 1% risk interval. The number of significant targets identified 
at the 1% risk interval was almost double than the False Discover Rate (FDR). This can 
be attributed to lack of mammary cell contamination from adipicytes that is achieved 
under culture conditions. Therefore, I concluded that primary mammary epithelial cell
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cultures serves microarray experiments better than utilizing in vivo (Chapter 4) glands 
and should be seriously taken into account in the experimental design of investigators.
All significant differentially expressed transcripts are presented in Figure 5.7 and 5.8. 
Molecules such as Jakl, bone morphogenic protein receptor type la (BMPrla), fibroblast 
growth factor receptor 1 (FGFrl), phospholipase A2 (Pla2gl2a), and Caveolin (Cav) 
show altered mRNA expression levels and have been linked to STAT signaling in the 
past.
Interaction between TGF-/3 and STATs is illustrated in this thesis once more in the level 
of Bone moiphogenic protein receptor type la (BMPrla) mRNA expression. BMPrla 
showed an induction in its mRNA in the Stat3+/* mice compared to wild types. Kawamura 
et al (2000) showed that BMP2 caused cell-cycle arrest and subsequent apoptosis of 
myeloma cells by up regulating levels of p21cipl/wa^  and p27kipI. In the same paper it was 
demonstrated that BMP2 treatment caused the inactivation of STAT3. Taken together 
with the above I hypothesize that over expression of BMPrla may results in activation of 
the BMP signaling pathway and induction of deregulation of cell development as 
observed in the Stat37’ mammary epithelial cells.
The same microarray data was analysed by means of Hierarchical clustering. Hielustering 
is producing some areas where there seems to be alteration of mRNA expression between 
Stat3+/' and wild types with most important been the Retinoblastoma-like protein (p i07). 
Hierarchical clustering indicated a down regulation of p i 07 in the Stat3+/‘mice compared 
to wild types. P I07 together with Retinoblatoma 1 and retinoblastoma-like 2 (pi30) play 
a pivotal role in regulating eukaryotic cell cycle progression, apoptosis, and terminal 
differentiation and inactivation of these molecules has been associated to abrogation of 
the cell cycle restriction point, leading to increased cell proliferation and apoptosis, and 
predisposing to cancer (MacPherson 2003, MacPherson 2004).
Affymetrix chip analysis and clustering are producing indications, facilitating a biologist 
to visualize alterations in gene expression profiles. As in Chapter 4, targets should be
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checked through laboratory experiments both in the RNA and protein level. 
Unfortunately, due to time constrains no further experimentation for confirmation of 
some of the above targets was undertaken. However, this analysis can provide valuable 
information for other investigators working on the STAT-signaling pathway and also 
indicate the usefulness of primary mammary cell cultures compared to in vivo RNA 
experiments.
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Chapter 6-Conclusion.
6.1 Introduction.
Apoptosis is an important and well-documented form of cell death that occurs in a 
variety of physiological and pathological conditions. This process has been known to 
play a key role in autoimmune diseases, carcinogenesis, cancer progression, and 
killing of cancer cells induced by chemotherapeutic drugs (Friesen 1996). Apoptosis 
represents a physiological event that is essential for homeostasis, and inappropriate 
apoptosis seems to be involved in many diseases (Carson 1993). Consequently, since 
control of apoptosis has been proposed as an important target for therapeutic 
intervention, the elucidation of the molecular pathways and mechanisms underlying 
this process is of primary interest.
Understanding of the molecular pathways responsible for controlling cell division, 
differentiation and apoptosis has been greatly facilitated by the use of transgenic 
animal technology. Transgenic technology offers the possibility of creating targeted 
gene mutations or over expression in genes of choice via germline manipulations. In 
particular, the generation of mice with targeted mutations in genes encoding proteins 
of interest has proved to be a useful way of elucidating the function of these gene 
products in vivo. Two of the most common uses of transgenic mice have been for (1) 
studies of tissue-specific and developmental stage-specific gene regulation and (2) for 
experiments of the phenotypic effects of transgene expression. Transgenic mouse 
models have provided some insight into the complex events contributing to cellular 
deregulation and the loss of growth control that can lead to tumorigenesis. They have 
also helped elucidate crucial roles for genes in development and normal tissue 
homeostasis.
Analysis of a conditional Smad4 transgenic mouse and how over expression of Smad4 
influences apoptosis in mammary epithelial cells during involution is the primary goal 
of this thesis. Based on results in the protein and mRNA level via western blots and 
microarrays respectively this project was expanded in the analysis of conditional 
knockout animals such as Stat3 and mbd2.
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Mammary gland was chosen as the tissue of choice for the analysis of the above 
named transgenic and knockout animals. Mammary gland possesses the unique 
phenomenon of repetitive cycling from full lactation to involution and back and thus 
elects it as an ideal model to study highly controlled in vivo cellular apoptosis.
6.2. Smads and Apoptosis.
Smad4 is the central mediator of the TGF-/3 superfamily signaling and the initial idea 
of addressing its role in mammary gland epithelial apoptosis (involution) was based 
on published data indicating the following; all TGF-/3 isoforms are expressed during 
all stages of mammary gland development except lactation (Robinson 1991). TGF-/3 
expression plays many important roles in mammary gland physiology including 
apoptosis during involution (Daniel 1996, Joseph 1999, Nguyen 2000). Furthermore, 
Smads have been shown in a number of different cellular environments to be capable 
of initiating apoptosis.
Smad4, the main molecule in question in this thesis, has been characterised as a tumor 
suppressor gene due to its frequent inactivation/mutation in pancreatic and colorectal 
cancers. Smad4 expression in Smad4-defective tumor cell lines has been shown to 
restore TGF-/3 signaling and induce cell cycle arrest and apoptosis (Dai 1999a). 
Schwarte-Waldhoff (1999) demonstrated the antiangiogenic role of Smad4 in tumor 
cell lines whilst Ramachandra (2002) demonstrated the role of Smad4 in the induction 
of apoptosis in a process termed anoikis. Conditional overexpression of Smad4 in the 
testis demonstrated amongst other apoptosis of germ cells and spermatogenic arrest 
indicating once more its role in apoptosis (Narula 2002). Finally, only recently Li 
(2004), demonstrated that lack of Smad4 in mouse mammary glands gradually 
induced cell proliferation, alveolar hyperplasia and transdifferentiation of mammary 
epithelial cells into squamous epithelial cells.
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6.2.1 Transgenic Analysis of Smad4.
Over expression of Smad4 has been directed specifically in mammary epithelial cells 
during involution. Protein induction, specificity of tissue and time duration has been 
achieved by the utilization of the ovine beta lactoglobulin promoter (BLG) (Whitelaw 
1992, Farini 1995, Clark 1992).
The initial analysis was to identify whether there is an altered epithelial cell 
contribution in mammary gland composition during involution between Smad4 
transgenic and wild type mice. For this purpose I generated H&E slides at Day 10 of 
lactation and Day 2, 3 and 6 of involution. Following quantification I identified a 
significant increase in epithelial cell death at both day 2 and 3 in the Smad4 
transgenics compared to wild types. TUNEL as well as quantification of apoptotic 
cells revealed that Smad4 transgenics are significantly inducing apoptosis at day 2 and 
3 of involution. This result comes into agreement with the altered phenotype observed 
in the same time points.
In an effort to elucidate which molecular mechanism(s) may facilitate this apoptosis I 
examined a number of known mediators of mammary gland development as well as 
some apoptosis regulatory factors. Western blot analysis for Stat3 indicated a 
significant up-regulation at day 2 involution in the Smad4 transgenic mice while at 
day 3 Stat3 levels were significantly down regulated. This result supports the Stat- 
Smad cooperation which has also been illustrated by others (Dai 1999, Philip 1996, 
Nakashima 1999). Based on these findings, I hypothesize that Stat3 gets induced by 
Smad4 at day 2 involution, a time point where there is a great remodelling of the 
gland. Stat3 facilitates cell death and remodelling and demonstrates its tumor 
suppressor activity. However, at day 3 involution Stat3 levels are down regulated in 
Smad4 transgenics compared to wild types. This changing mode of Stat3 can be 
attributed to the survival factors influencing epithelial cells probably by generalised 
gland stimuli that remain to be identified.
Stat5a is a protein responsible for regulation of milk protein gene levels. Furthermore, 
it has been shown that Stat5a promotes cell survival and its loss results in increased 
apoptosis during mammary gland involution. Thereafter, it comes to no surprise that
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levels of Stat5a are induced in both genotypes at day 10 lactation compared to 
involution. During lactation epithelial cells are fully functional in producing milk and 
Stat5a is a protein that facilitates this process. However, at day 2 and 3 of involution 
Stat5a levels are significantly induced in the Smad4 mice compared to wild types, a 
result which supports again Smad-Stat cooperation and possibly can be explained as a 
self defence mechanism of epithelial cells to survive.
Western blots indicated p27kipl as the cyclin-dependant kinase responsible for 
accelerated cell death during day 2 and 3 of involution in the Smad4 transgenic 
animals compared to controls. Levels ofp27kipl were increased during this time points 
in the transgenics animals indicating that increased apoptosis influenced by Smad4 is 
a retinoblastoma dependent pathway. It was surprising to see that p21 levels were 
absent both in the protein and mRNA levels. Finally, Bax, an important mammary 
apoptotic signal was investigated via western blotting. Bax levels were present 
throughout involution without indicating significant changes in its expression between 
Smad4 and wild type animals except of day 3 of involution.
I have performed primary mammary cell cultures in order to investigate a) the 
consequence of Smad4 over expression in epithelial cell cycle and apoptosis and b) 
the influences that TGF-/3 administration can have in a Smad4 over expressing 
environment in vitro. Primary cell cultures performed with glands taken from day 15- 
17 old pregnant mice. Unfortunately, I discovered that the BLG-Smad4 construct 
expression in the mRNA level was absent.
6.2.2 Future work.
Future work with this model can be centre on a biochemical analysis of Smad proteins 
(R-Smads 1, 2 and phospho-2 and the I-Smads 6 and Smad7). Smad4 has shown that 
can play an important role in inducing mammary epithelial cell apoptosis. The 
detailed investigation of the Smad-Stat interplay appears to be of great importance. 
Electrophoretic Mobility Swift Assays (EMSA) should be performed in an effort to 
understand the binding properties and the level of collaboration between the Smad4/3 
and Stat3 in different developmental stages of the mammary gland. Furthermore, a
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very interesting experiment will be to “boost” the whole TGF-/3 signaling pathway by 
crossing/passing the BLG-Smad4 construct to conditionally transgenic mice for TGF- 
/3. Another interesting experiment will be through the facilitation of siRNA 
technology in primary mammary epithelial cell cultures. In this way Smad4 can be 
knocked out and a series of analysis in both RNA and protein level can be undertaken.
6.3 Microarray analysis of Smad4.
In an attempt to investigate levels of molecules known to interact with the Smads and 
furthermore identify new targets of the Smad signaling pathway I performed a 
microarray analysis from day 3 involuting mammary glands. Day 3 was chosen as the 
time point of choice based on the phenotypic and molecular changes observed in my 
initial analysis. Following data normalisation and statistical analysis, Vitamin D 
receptor (VDR) was indicated as a molecule that gets induced by Smad4 over 
expression. Levels of VDR were analysed both in the mRNA and protein level by 
semi-quantitative RT-PCR and western blot analysis respectively at day 3 of 
involution. I was able to confirm Affymetrix’s result by identifying an up-regulation 
of VDR levels at day 3 involution in the Smad4 transgenics compared to controls at 
both RNA and protein levels.
Cooperation between VDR and Smads comes to no surprise as this interaction has 
been illustrated by others (Yanagisawa 1999, Yanagi 1999). More specifically, Smad3 
acts as a co-activator of VDR and positively regulates its pathway which is 
characterised by growth inhibition of cancer cells as well as inhibition of breast 
tumorigenesis (Issa 1998).
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6.3.1 Future Work.
It will be of great importance if  microarray experiments could be performed in earlier 
time points e.g. day 1 or 2 of involution. This will create a better understanding about 
the influence of Smad4 during involution. Experimentation should also be undertaken 
in elucidating the detailed mechanism of VDR activation by Smad4. Issa (1998) 
demonstrated a VDR induction by Smad3. EMSA can identify whether Smad3 or 
Smad4 binding can induce VDR expression.
6.3.2 The MBD2 mouse.
Raw Affymetrix data indicated a down regulation of MBD2 gene expression at day 3 
of involution in the Smad4 transgenic mice. I utilised conditional knockout MBD2 
mice in an attempt to investigate the consequences of MBD2 depletion in the 
mammary gland during its development and involution. No phenotypic differences 
were identified in any case between knockouts and wild types. Despite the lack of 
phenotypic differences between MBD2 knockouts and wild types it would be 
interesting to analyse the consequences o f an MBD2 over expressing mouse due to 
the fact that this molecule has been associated to various cancers (Magdinier and 
Wolffe 2001, Sansom 2003).
6.4 Smad4-Stat3 Interactions at Day 3 Involution.
In Chapter 3 ,1 demonstrated a down regulation of Stat3 in the Smad4 transgenic mice 
at the 3rd day of involution. It has been shown by others that Smads and Stats are two 
cytokines that exert antagonistic effects on fibroblasts (Ghosh 2001) and that Statl 
induces Smad7 (I-Smad) up-regulation. Synergistic signaling between Smads and 
Stats is indirect facilitated through the p300 co-activator (Ulloa 1999). Furthermore, 
Stat3 knockout mice in the mammary gland have shown a delay in involution 
(Chapman 1999).
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Based on the above, it seemed appropriate to “pass” the BLG-Smad4 construct in 
mice deficient for Stat3 in the mammary gland. My hypothesis was that over 
expression of Smad4 could rescue Stat3’s delayed involution. H&E slides were 
generated and fat contribution between Blg-Cre-Smad4-Blg-Cre Stat^' and Blg-Cre 
Stat3^' showed no differences. Furthermore, apoptotic levels were also counted 
between these two genotypes and revealed no differences between the two genotypes.
I can conclude from the above result that over expression of Smad4 in a Stat3 null 
environment cannot restore physiological levels of apoptosis and rescue Stat3’s 
delayed involution. Further experimentation is necessary for identifying relative levels 
of various cellular co-activators and transcription factors that may govern this net 
effect. Of particular interest will be the performance of an Electrophoretic Mobility 
Shift Assay (EMSA), investigating the binding of Smad3/4 and Stat3 on the p300 co­
activator. Binding levels of these two molecules will facilitate the elucidation of the 
overall interaction and provide valuable information on how over expression of 
Smad4 can influence Stat3’s physiological role in the mammary gland.
6.5 Stat3 Microarrays.
A scaled microarray approach was undertaken in an attempt to identify new and check 
known targets influenced by Stat3 depletion in the mammary gland. Contrary to 
Smad4’s microarray experiments I performed primary mammary epithelial cell 
cultures in an attempt to avoid fat contamination. Stat3'7' mammary epithelial cells 
exhibited inability to cluster and to reach adequate confluency levels for RNA 
extraction.
Stat3+/‘ mammary epithelial cells were subjected to Affymetrix hybridization and 
compared to Stat3 wild types. Data analysis following filtering and normalization 
indicated a number of significant altered targets like the Bone Morphogenetic receptor 
la (BMPrla) and Jakl whilst average hierarchical clustering identified amongst 
others a down regulation of the retinoblastoma-like 1 expression. For BMPrla, further 
experimentation identifying levels and distribution should be undertaken via western
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blotting and immunohistochemistry. Based on the observation that Stat3'/_ mice 
exhibited inability to colonise time lapse microscopy as well as cell cycle studies 
should be undertaken in order to investigate and provide valuable information about 
the modulators of this phenomenon. Further experimentation should be undertaken 
regarding the down regulation of the retinoblastoma-like 1 gene and a possible 
strategy would be to utilise tools such as siRNA.
6.6 Conclusions.
In this thesis I have attempted to describe an analysis of the role of Smad4 in the 
murine mammary gland involution. This was undertaken by utilizing conditional 
transgenic animals for Smad4. Based on my data this investigation was directed 
towards Smad-Stat interactions as well as MBD2 by the utilization of conditional 
knockout animals. Characterisation of the animal models is a lengthy process and was 
never going to be completed within the realms of a 3-year Ph.D. However, in the near 
future I hope that information can be gained from all models which will be 
constructive in determining what role Smad4, Stat3 and MBD2 plays in mammary 
gland lactation and involution.
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